Author: "Céline Dard" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Céline Dard"' showing total 48 results

Start Over Author "Céline Dard"

48 results on '"Céline Dard"'

1. Corrigendum: Glycolysis Changes in Alloreactive Memory B Cells in Highly Sensitized Kidney Transplant Recipients Undergoing Desensitization Therapy

Author: Johan Noble, Lara Cabezas, Aurelie Truffot, Lucile Dumolard, Thomas Jouve, Paolo Malvezzi, Lionel Rostaing, Céline Dard, Philippe Saas, Paolo Cravedi, and Zuzana Macek-Jilkova
Subjects: donor-specific antibody, desensitization, kidney transplantation, metabolism, memory B cells, glycolysis, Specialties of internal medicine, RC581-951
Published: 2024
Full Text: View/download PDF

2. Glycolysis Changes in Alloreactive Memory B Cells in Highly Sensitized Kidney Transplant Recipients Undergoing Desensitization Therapy

Author: Johan Noble, Lara Cabezas, Aurelie Truffot, Lucile Dumolard, Thomas Jouve, Paolo Malvezzi, Lionel Rostaing, Céline Dard, Philippe Saas, Paolo Cravedi, and Zuzana Macek-Jilkova
Subjects: donor-specific antibody, desensitization, kidney transplantation, metabolism, memory B cells, glycolysis, Specialties of internal medicine, RC581-951
Abstract: Despite the growing use of desensitization strategies, hyperimmune patients remain at high risk of antibody-mediated rejection suggesting that, even when donor-specific antibodies (DSA) are effectively depleted, anti-donor specific B cells persist. We included 10 highly sensitized recipients that underwent desensitization with plasmapheresis and B cell depletion prior to kidney transplantation. We quantified changes in DSA (luminex), total B-cell subsets (flow cytometry), anti-donor HLA B cells (fluorospot), and single-cell metabolism in serially collected samples before desensitization, at the time of transplant, and at 6 and 12 months thereafter. Desensitization was associated with a decrease in DSA and total memory B cell and naive B cell percentage, while plasma cells and memory anti-donor HLA circulating B cells persisted up to 12 months after transplant. At 12-month post-transplantation, memory B cells increased their glycolytic capacity, while proliferative KI67+ plasma cells modified their metabolism by increasing fatty acid and amino acid oxidation capacity and decreasing their glucose dependence. Despite effective DSA depletion, anti-donor B cells persist in kidney transplant recipients. Due to the reliance of these cells on glycolysis, glycolysis-targeting therapies might represent a valuable treatment strategy.
Published: 2024
Full Text: View/download PDF

3. The recent introduction of Angiostrongylus cantonensis and its intermediate host Achatina fulica into Guadeloupe detected by phylogenetic analyses

Author: Gelixa Gamiette, Séverine Ferdinand, David Couvin, Céline Dard, and Antoine Talarmin
Subjects: Angiostrongylus cantonensis, Achatina fulica, Guadeloupe, Phylogeny, Cytochrome C, Cytochrome B, Infectious and parasitic diseases, RC109-216
Abstract: Abstract Background Angiostrongylus cantonensis (rat lungworm) is the main pathogen responsible for eosinophilic meningitis in humans. One of its intermediate snail hosts, Achatina fulica, was already present in many countries around the world before it appeared in the West Indies in the late 1980s. In the French territories in the Caribbean and northern South America, the first cases of human neuroangiostrongyliasis were reported in Martinique, Guadeloupe and French Guiana in 2002, 2013 and 2017, respectively. In order to better characterize angiostrongyliasis in Guadeloupe, particularly its geographical origin and route of introduction, we undertook molecular characterization of adult worms of Angiostrongylus cantonensis and its intermediate host Achatina fulica. Methods Genomic DNA of adult Angiostrongylus cantonensis and Achatina fulica was extracted and amplified by polymerase chain reaction (PCR) targeting the mitochondrial genes cytochrome B and C for A. cantonensis and 16S ribosomal RNA for A. fulica. The PCR products were sequenced and studied by phylogenetic analysis. Results Cytochrome B and cytochrome C molecular markers indicate a monophyletic lineage of A. cantonensis adult worms in Guadeloupe. Two sequences of A. fulica were identified. Conclusions These results confirm the recent introduction of both Angiostrongylus cantonensis and Achatina fulica into Guadeloupe. Achatina fulica in Guadeloupe shares a common origin with those in Barbados and New Caledonia, while Angiostrongylus cantonensis in Guadeloupe shares a common origin with those in Brazil, Hawaii and Japan. Graphical Abstract
Published: 2023
Full Text: View/download PDF

4. Correction: A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication?

Author: Podjanee Jittamala, Wuelton Monteiro, Menno R Smit, Belen Pedrique, Sabine Specht, Carlos J Chaccour, Céline Dard, Pascal Del Giudice, Virak Khieu, Annabel Maruani, Virgilio E Failoc-Rojas, Marimar Sáez-de-Ocariz, Antoni Soriano-Arandes, Jaime Piquero-Casals, Anne Faisant, Marie-Pierre Brenier-Pinchart, David Wimmersberger, Jean T Coulibaly, Jennifer Keiser, Franck Boralevi, Oliver Sokana, Michael Marks, Daniel Engelman, Lucia Romani, Andrew C Steer, Lorenz von Seidlein, Nicholas J White, Eli Harriss, Kasia Stepniewska, Georgina S Humphreys, Kalynn Kennon, Philippe J Guerin, and Kevin C Kobylinski
Subjects: Arctic medicine. Tropical medicine, RC955-962, Public aspects of medicine, RA1-1270
Abstract: [This corrects the article DOI: 10.1371/journal.pntd.0009144.].
Published: 2023
Full Text: View/download PDF

5. A brain cyst load-associated antigen is a Toxoplasma gondii biomarker for serodetection of persistent parasites and chronic infection

Author: Céline Dard, Christopher Swale, Marie-Pierre Brenier-Pinchart, Dayana C. Farhat, Valeria Bellini, Marie Gladys Robert, Dominique Cannella, Hervé Pelloux, Isabelle Tardieux, and Mohamed-Ali Hakimi
Subjects: Toxoplasma gondii, Toxoplasmosis, Biomarker, Chronic infection, Serology, Recombinant antigen, Biology (General), QH301-705.5
Abstract: Abstract Background Biomarker discovery remains a major challenge for predictive medicine, in particular, in the context of chronic diseases. This is true for the widespread protozoan Toxoplasma gondii which establishes long-lasting parasitism in metazoans, humans included. This microbe successively unfolds distinct genetic programs that direct the transition from high to low replicative potential inside host cells. As a slow-replicating cell, the T. gondii bradyzoite developmental stage persists enclosed in a cyst compartment within tissues including the nervous system, being held by a sustained immune equilibrium which accounts for the prolonged clinically silent phase of parasitism. Serological surveys indicate that nearly one third of the human population has been exposed to T. gondii and possibly host bradyzoites. Because any disruption of the immune balance drives the reverse transition from bradyzoite to fast replicating tachyzoite and uncontrolled growth of the latter, these people are at risk for life-threatening disease. While serological tests for discriminating recent from past infection are available, there is yet no immunogenic biomarker used in the serological test to allow ascertaining the presence of persistent bradyzoites. Results Capitalizing on genetically engineered parasites induced to produce mature bradyzoites in vitro, we have identified the BCLA/MAG2 protein being restricted to the bradyzoite and the cyst envelope. Using laboratory mice as relevant T. gondii host models, we demonstrated that BCLA/MAG2 drives the generation of antibodies that recognize bradyzoite and the enveloping cyst structure. We have designed an ELISA assay based on a bacterially produced BCLA recombinant polypeptide, which was validated using a large collection of sera from mice of different genetic backgrounds and infected with bcla+ or bcla-null cystogenic and non-cystogenic T. gondii strains. To refine the design of the ELISA assay, we applied high-resolution BCLA epitope mapping and identified a specific combination of peptides and accordingly set up a selective and sensitive ELISA assay which allowed the detection of anti-BCLA/MAG2 antibodies in the sera of human patients with various forms of toxoplasmosis. Conclusions We brought proof of principle that anti-BCLA/MAG2 antibodies serve as specific and sensitive serological markers in the perspective of a combinatorial strategy for detection of persistent T. gondii parasitism.
Published: 2021
Full Text: View/download PDF

6. Early Blood Transfusion After Kidney Transplantation Does Not Lead to dnDSA Development: The BloodIm Study

Author: Thomas Jouve, Johan Noble, Hamza Naciri-Bennani, Céline Dard, Dominique Masson, Gaëlle Fiard, Paolo Malvezzi, and Lionel Rostaing
Subjects: kidney transplantation, induction treatment, blood transfusion, HLA sensitization, anti-thymocyte globulin (ATG), Immunologic diseases. Allergy, RC581-607
Abstract: Outcomes after kidney transplantation are largely driven by the development of de novo donor-specific antibodies (dnDSA), which may be triggered by blood transfusion. In this single-center study, we investigated the link between early blood transfusion and dnDSA development in a mainly anti-thymocyte globulin (ATG)-induced kidney-transplant cohort. We retrospectively included all recipients of a kidney transplant performed between 2004 and 2015, provided they had >3 months graft survival. DSA screening was evaluated with a Luminex assay (Immucor). Early blood transfusion (EBT) was defined as the transfusion of at least one red blood-cell unit over the first 3 months post-transplantation, with an exhaustive report of transfusion. Patients received either anti-thymocyte globulins (ATG) or basiliximab induction, plus tacrolimus and mycophenolic acid maintenance immunosuppression. A total of 1088 patients received a transplant between 2004 and 2015 in our center, of which 981 satisfied our inclusion criteria. EBT was required for 292 patients (29.7%). Most patients received ATG induction (86.1%); the others received basiliximab induction (13.4%). dnDSA-free graft survival (dnDSA-GS) at 1-year post-transplantation was similar between EBT+ (2.4%) and EBT- (3.0%) patients (chi-squared p=0.73). There was no significant association between EBT and dnDSA-GS (univariate Cox’s regression, HR=0.88, p=0.556). In multivariate Cox’s regression, adjusting for potential confounders (showing a univariate association with dnDSA development), early transfusion remained not associated with dnDSA-GS (HR 0.76, p=0.449). However, dnDSA-GS was associated with pretransplantation HLA sensitization (HR=2.25, p=0.004), hemoglobin >10 g/dL (HR=0.39, p=0.029) and the number of HLA mismatches (HR=1.26, p=0.05). Recipient’s age, tacrolimus and mycophenolic-acid exposures, and graft rank were not associated with dnDSA-GS. Early blood transfusion did not induce dnDSAs in our cohort of ATG-induced patients, but low hemoglobin level was associated with dnDSAs-GS. This suggests a protective effect of ATG induction therapy on preventing dnDSA development at an initial stage post-transplantation.
Published: 2022
Full Text: View/download PDF

7. A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication?

Author: Podjanee Jittamala, Wuelton Monteiro, Menno R Smit, Belen Pedrique, Sabine Specht, Carlos J Chaccour, Céline Dard, Pascal Del Giudice, Virak Khieu, Annabel Maruani, Virgilio E Failoc-Rojas, Marimar Sáez-de-Ocariz, Antoni Soriano-Arandes, Jaime Piquero-Casals, Anne Faisant, Marie-Pierre Brenier-Pinchart, David Wimmersberger, Jean T Coulibaly, Jennifer Keiser, Franck Boralevi, Oliver Sokana, Michael Marks, Daniel Engelman, Lucia Romani, Andrew C Steer, Lorenz von Seidlein, Nicholas J White, Eli Harriss, Kasia Stepniewska, Georgina S Humphreys, Kalynn Kennon, Philippe J Guerin, and Kevin C Kobylinski
Subjects: Arctic medicine. Tropical medicine, RC955-962, Public aspects of medicine, RA1-1270
Abstract: BackgroundOral ivermectin is a safe broad spectrum anthelminthic used for treating several neglected tropical diseases (NTDs). Currently, ivermectin use is contraindicated in children weighing less than 15 kg, restricting access to this drug for the treatment of NTDs. Here we provide an updated systematic review of the literature and we conducted an individual-level patient data (IPD) meta-analysis describing the safety of ivermectin in children weighing less than 15 kg.Methodology/principal findingsA systematic review was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) for IPD guidelines by searching MEDLINE via PubMed, Web of Science, Ovid Embase, LILACS, Cochrane Database of Systematic Reviews, TOXLINE for all clinical trials, case series, case reports, and database entries for reports on the use of ivermectin in children weighing less than 15 kg that were published between 1 January 1980 to 25 October 2019. The protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO): CRD42017056515. A total of 3,730 publications were identified, 97 were selected for potential inclusion, but only 17 sources describing 15 studies met the minimum criteria which consisted of known weights of children less than 15 kg linked to possible adverse events, and provided comprehensive IPD. A total of 1,088 children weighing less than 15 kg were administered oral ivermectin for one of the following indications: scabies, mass drug administration for scabies control, crusted scabies, cutaneous larva migrans, myiasis, pthiriasis, strongyloidiasis, trichuriasis, and parasitic disease of unknown origin. Overall a total of 1.4% (15/1,088) of children experienced 18 adverse events all of which were mild and self-limiting. No serious adverse events were reported.Conclusions/significanceExisting limited data suggest that oral ivermectin in children weighing less than 15 kilograms is safe. Data from well-designed clinical trials are needed to provide further assurance.
Published: 2021
Full Text: View/download PDF

8. Chronic toxoplasmosis and sleepiness in obstructive sleep apnea: Is there a link?

Author: Céline Dard, Sébastien Bailly, Jean-Louis Pépin, Marie-Pierre Brenier-Pinchart, Hélène Fricker-Hidalgo, Marie Peeters, Hervé Pelloux, and Renaud Tamisier
Subjects: Medicine, Science
Abstract: INTRODUCTION:Sleepiness is the main clinical expression of obstructive sleep apnea (OSA) syndrome resulting from upper airway collapse. Recent studies have discussed the fact that the presence of T. gondii cysts in the brain and the resulting biochemical and immunological mechanisms could be linked to neurobehavioral disorders. The aim of the present study was to explore the potential impact of chronic toxoplasmosis on sleepiness and on obstructive sleep apnea (OSA) severity in OSA obese patients. MATERIALS AND METHODS:A case control study on obese patients screened for OSA was performed. According to the sleep disorder and matched based on gender, age and body mass index (BMI), two groups of obese patients were selected from our sample collection database. All patients were tested for toxoplasmosis serological status measuring anti-Toxoplasma IgG and IgM levels. Univariable and multivariable logistic regression models were performed to assess the impact of chronic toxoplasmosis on sleepiness and OSA severity. RESULTS:107 obese patients suffering from OSA were included in the study (median age: 53.3 years Interquartile range (IQR): [41.9-59.9]; median BMI: 39.4 kg/m2 IQR: [35.5-44.1], apnea-hypopnea index = 27.5 events/h [10.7-49.9]). Chronic toxoplasmosis was present in 63.4% and 70.7% of patients with or without sleepiness (p = 0.48), respectively and was not associated either to sleepiness (OR: 0.76, 95% CI: [0.52; 2.33], p = 0.64) or OSA severity (OR = 1.75, 95% CI: [0.51; 5.98] p = 0.37). CONCLUSION:Although chronic Toxoplasma infection in immunocompetent humans has been associated to several behavioral disorders or pathologies in recent literature, we demonstrate here that chronic toxoplasmosis is not associated to sleepiness and to sleep apnea syndrome severity in obese patients suspected of sleep apnea syndrome.
Published: 2020
Full Text: View/download PDF

9. Crossing of the Cystic Barriers of Toxoplasma gondii by the Fluorescent Coumarin Tetra-Cyclopeptide

Author: Céline Dard, Baptiste Leforestier, Flaviane Francisco Hilário, Mohamed Dit Mady Traoré, Marie-Ange Lespinasse, Basile Pérès, Marie-Carmen Molina, Rossimiriam Pereira de Freitas, Anne Milet, Danièle Maubon, and Yung-Sing Wong
Subjects: cyclopeptides, histone deacetylase, Toxoplasma gondii, bradyzoite, cell-permeable agent, molecular dynamics, Organic chemistry, QD241-441
Abstract: FR235222 is a natural tetra-cyclopeptide with a strong inhibition effect on histone deacetylases, effective on mammalian cells as well as on intracellular apicomplexan parasites, such as Toxoplasma gondii, in the tachyzoite and bradyzoite stages. This molecule is characterized by two parts: the zinc-binding group, responsible for the binding to the histone deacetylase, and the cyclic tetrapeptide moiety, which plays a crucial role in cell permeability. Recently, we have shown that the cyclic tetrapeptide coupled with a fluorescent diethyl-amino-coumarin was able to maintain properties of cellular penetration on human cells. Here, we show that this property can be extended to the crossing of the Toxoplasma gondii cystic cell wall and the cell membrane of the parasite in its bradyzoite form, while maintaining a high efficacy as a histone deacetylase inhibitor. The investigation by molecular modeling allows a better understanding of the penetration mechanism.
Published: 2021
Full Text: View/download PDF

10. Angiostrongylus cantonensis Infection of Central Nervous System, Guiana Shield

Author: Antoine L. Defo, Noémie Lachaume, Emma Cuadro-Alvarez, Chimène Maniassom, Elise Martin, Falucar Njuieyon, Fanny Henaff, Yajaira Mrsic, Annabelle Brunelin, Loic Epelboin, Denis Blanchet, Dorothée Harrois, Nicole Desbois-Nogard, Yvonne Qvarnstrom, Magalie Demar, Céline Dard, and Narcisse Elenga
Subjects: Angiostrongylus cantonensis, nematodes, parasites, eosinophilic meningitis, transverse myelitis, Guiana Shield, Medicine, Infectious and parasitic diseases, RC109-216
Abstract: We report a case of eosinophilic meningitis complicated by transverse myelitis caused by Angiostrongylus cantonensis in a 10-year-old boy from Brazil who had traveled to Suriname. We confirmed diagnosis by serology and real-time PCR in the cerebrospinal fluid. The medical community should be aware of angiostrongyliasis in the Guiana Shield.
Published: 2018
Full Text: View/download PDF

11. First report of a possible abdominal Angiostrongylus costaricensis in a French expatriate in the French Amazon

Author: Anissa Desmoulin, Alessia Melzani, Céline Dard, Mathieu Nacher, Félix Djossou, Mohamed Kinan Drak Alsibai, and Loïc Epelboin
Subjects: General Medicine
Abstract: Abdominal angiostrongyliasis is a parasitic disease caused by Angiostrongylus costaricensis. Cases have been reported from Texas to southern Argentina but not in the eastern part of the Amazon. We present the case of a 34-year-old French man living in French Guiana who had travelled to the Caribbean.
Published: 2022

12. Biobanking in a histocompatibility laboratory. Guidelines from the Francophone Society of Histocompatibility and Immunogenetics (SFHI)

Author: Nicolas Guillaume, Christophe Picard, Camille Humeau, Dominique Masson, Jean-Luc Taupin, Alice Aarnink, Céline Thévenin, Virginie Renac, Barbara Proust, Céline Dard, and Alexandre Walencik
Subjects: medicine.medical_specialty, business.industry, Therapeutic treatment, French, General Medicine, Immunogenetics, Immune Dysfunction, Biobank, language.human_language, Organ transplantation, Histocompatibility, Family medicine, language, Humans, Medicine, Laboratories, business, Biological Specimen Banks, Retrospective Studies
Abstract: Histocompatibility laboratories perform the biological analyses linked related to organ transplant, hematopoietic stem cells transplant, some immune dysfunction diseases and immuno-allergy after therapeutic treatment. Most of these analyses are prospectively or retrospectively performed on sera and DNA. The Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) has made some recommendations in order to define storage conditions and storage lifetime of the samples required in a histocompatibility laboratory. These recommendations have been drawn up by a working group of ten biologists. They have been established on literature review and data from method validation, which has been already performed within French laboratories (collected through a national questionnaire sent to participant laboratories). The recommendations made by the SFHI for the storage of samples for immunogenetics analyses facilitate the harmonization of practices among histocompatibility laboratories.
Published: 2021

13. Performance of a Toxo IgM prototype assay for the diagnosis of maternal and congenital Toxoplasma infections

Author: Hélène Fricker-Hidalgo, Céline Dard, Claire Bailet, Marie-Pierre Brenier-Pinchart, Emmanuelle Chapey, Hervé Pelloux, and Martine Wallon
Subjects: 0301 basic medicine, 030106 microbiology, Clinical Biochemistry, Antibodies, Protozoan, Acute infection, Context (language use), Immunologic Tests, Toxoplasmosis, Congenital, Serology, 03 medical and health sciences, 0302 clinical medicine, Pregnancy, medicine, Humans, 030212 general & internal medicine, Seroconversion, biology, business.industry, Biochemistry (medical), Toxoplasma gondii, General Medicine, biology.organism_classification, medicine.disease, Toxoplasmosis, Immunoglobulin M, Pregnancy Complications, Parasitic, Immunology, biology.protein, Female, Antibody, business, Toxoplasma
Abstract: Background Testing for anti-Toxoplasma immunoglobulin (Ig)M is of main importance in the context of pregnancy to promptly alert to an acute maternal infection prior to the detection of IgG and to identify infected newborns. Their absence helps exclude a recent maternal infection in the presence of IgG. Methods The performance of a Toxo IgM immunocapture prototype assay (bioMérieux, France) was compared with that of the VIDAS® Toxo IgM and the ARCHITECT® Toxo IgM (Abbott, Germany) assays at Grenoble and Lyon (France). A total of 1446 sera were sampled from (i) 1054 pregnant women found by routine workup to have no infection (n = 843), an acute infection (4 months) with residual (n = 120) or no IgM (n = 62); (ii) 50 three-serum panels sampled immediately after a maternal seroconversion; (iii) 242 samples taken in 41 children with a congenital toxoplasmosis (n = 122) and in 40 uninfected children (n = 120). Results In pregnant women, the overall agreement with the VIDAS® assay was 99.23% (CI: 99.16–99.27) and that with the ARCHITECT® assay was 99.14% (CI: 99.07–99.17). Sensitivity of the Toxo IgM prototype assay was 100% (CI: 87.66–100.00) and specificity was 99.64% (98.96–99.93). In acute maternal infections, IgM assays were detected as early with the prototype as with the other two. In the congenitally infected children, IgM were detected on their first sample in 25/40 with the prototype vs. 23/40 with the VIDAS® test. No uninfected child had positive IgM. Conclusion The prototype performed comparably to the ARCHITECT® and VIDAS® Toxo IgM assays for the diagnosis of maternal and congenital toxoplasmosis.
Published: 2020

14. Tocilizumab Evaluation in HLA-Desensitization before Kidney Transplantation as an Add-On Therapy to Apheresis: The TETRA Study

Author: Thomas Jouve, Mélanie Daligault, Johan Noble, Florian Terrec, Farida Imerzoukene, Céline Dard, Béatrice Bardy, Paolo Malvezzi, and Lionel Rostaing
Subjects: desensitization, kidney transplantation, tocilizumab, anti-HLA alloantibodies, MFI, General Medicine
Abstract: Background: Desensitization strategies improve access to transplantation in highly sensitized kidney transplant candidates. Tocilizumab could be a valuable addition to more traditional desensitization regimens. We investigated the effect of tocilizumab as an add-on therapy to our standard of care (SoC) desensitization strategy based on rituximab and apheresis. Methods: In this study, we prospectively included highly sensitized patients to receive monthly tocilizumab infusions for 6 months before our SoC regimen (Toci + SoC group). We compared the reductions in the mean fluorescent intensity (MFI) rebound at post-transplantation and kidney function at 1-year post-transplantation to patients treated by SoC (based on apheresis and two doses of rituximab). Results: Twenty-six patients were included in the SoC group; seven in the Toci + SoC group. Reductions in pre-transplantation MFI were similar between groups. At 1-year post-transplantation, there was no absolute difference in overall MFI rebounds, including donor-specific antibodies. Toci + SoC helped lower the rebound of antibodies with more elevated baseline MFIs. Graft function and survival rates were similar at one-year post-transplantation (median eGFR 62.8 vs. 65.6 mL/min/1.73 m2 for SoC and Toci + SoC, respectively). Conclusions: Tocilizumab as an add-on to SoC desensitization may help control the post-transplantation rebound of antibodies with elevated baseline MFIs. However, reductions in pre-transplantation MFIs were similar with or without tocilizumab. Further studies are needed to validate this pilot study.
Published: 2023

15. Comment faire face à un événement inattendu pouvant modifier l’activité normale de thérapie cellulaire ? Recommandations de la Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

Author: Yves Beguin, Yves Chalandon, Séverine Sauze, Céline Dard, Jacques-Olivier Bay, Alexandre Carpentier, Thierry Guillaume, Ibrahim Yakoub-Agha, Hélène Labussière-Wallet, and Marie Noëlle Lacassagne
Subjects: 0301 basic medicine, Cancer Research, Évènements inattendus, Cell Transplantation, Immunotherapy, Adoptive, Health Services Accessibility, Unexpected event, 03 medical and health sciences, 0302 clinical medicine, Humans, Radiology, Nuclear Medicine and imaging, Allogeneic/autologous hematopoietic cell transplantation, Pandemics, CAR-T Cells, Societies, Medical, Bone Marrow Transplantation, Cryopreservation, Receptors, Chimeric Antigen, SARS-CoV-2, Hematopoietic Stem Cell Transplantation, Synthèse, Allogreffe/autogreffe de cellules souches hématopoïétiques, COVID-19, Hematology, General Medicine, Disaster plan, Tissue Donors, 030104 developmental biology, Cellules CAR-T, Oncology, 030220 oncology & carcinogenesis, Plan d’urgence sanitaire
Abstract: Resume L’epidemie mondiale de SARS-CoV-2 (COVID-19) a rapidement impacte l’ensemble de l’activite de therapie cellulaire a travers le monde. Non seulement, cet evenement inattendu etait une menace pour les patients ayant deja recu une greffe de cellules hematopoietiques ou une autre therapie cellulaire telle que les cellules CAR-T, mais egalement, il a ete responsable d’une desorganisation des activites de therapie cellulaire en raison de la dangerosite du virus et du manque de donnees scientifiques solides quant au mangement des patients et des donneurs. La Societe Francophone de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) a consacre un atelier pour produire des recommandations utiles en cas de survenu d’un tel evenement dans le but d’harmoniser les actions de tous les acteurs impliques pour que l’on puisse faire face collectivement dans le futur aux defis qui pourraient menacer notre activite. Ce travail n’est pas specifiquement dedie a l’epidemie de SARS-CoV-2, mais cette derniere a ete utilisee comme un exemple concret d’un evenement inattendu pour construire nos refletions et nos recommandations.
Published: 2021

16. Characterization of the novel <scp> HLA‐DQB1*05:236N </scp> null allele in a French hematopoietic stem cell donor

Author: Céline Dard, Ornella Senoussi, Dominique Masson, Béatrice Bardy, and Vincent Elsermans
Subjects: musculoskeletal diseases, Human leucocyte antigen, HLA-DQB1, Base Sequence, endocrine system diseases, Immunology, nutritional and metabolic diseases, Hematopoietic stem cell, Nucleotide substitution, Sequence Analysis, DNA, Human leukocyte antigen, Biology, Hematopoietic Stem Cells, Null allele, Molecular biology, Exon, medicine.anatomical_structure, immune system diseases, Genetics, medicine, HLA-DQ beta-Chains, Immunology and Allergy, skin and connective tissue diseases, Alleles
Abstract: HLA-DQB1*05:236N differs from HLA-DQB1*05:03:01:01 by one nucleotide substitution at codon 34.1 in exon 2.
Published: 2020

17. Characterization of two novel <scp>HLA</scp> alleles, <scp> C03:03:58 </scp> and <scp> DQB106:288 </scp> , in a French hematopoietic stem cell donor

Author: Céline Dard, Béatrice Bardy, Vincent Elsermans, Dominique Masson, and Ornella Senoussi
Subjects: Human leucocyte antigen, medicine.anatomical_structure, Immunology, Genetics, medicine, Immunology and Allergy, Hematopoietic stem cell, Human leukocyte antigen, Allele, Biology, Molecular biology
Published: 2020

18. Pythiosis: Case report leading to new features in clinical and diagnostic management of this fungal-like infection

Author: Anne Cécile Normand, Diane Bernheim, Danièle Maubon, Renaud Piarroux, Damien Dupont, Muriel Cornet, Christophe Chiquet, Céline Dard, Florent Aptel, CHU Grenoble, Centre de recherche en neurosciences de Lyon (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hypoxie : Physiopathologie Respiratoire et Cardiovasculaire (HP2 ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Service de parasitologie - mycologie [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), and Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])
Subjects: 0301 basic medicine, Microbiology (medical), medicine.medical_specialty, Antibiotic regimen, Antifungal drugs, [SDV]Life Sciences [q-bio], 030106 microbiology, Infectious Keratitis, Pythium insidiosum, Aquatic organisms, Keratitis, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, Pythiosis, 0302 clinical medicine, Medicine, lcsh:RC109-216, 030212 general & internal medicine, biology, business.industry, General Medicine, MALDI-TOF Mass Spectrometry, medicine.disease, biology.organism_classification, Dermatology, 3. Good health, Infectious Diseases, business
Abstract: A 21-year-old man developed infectious keratitis after swimming in Spain whilst wearing contact lenses. Mycelial growth from a corneal sample suggested keratomycosis, but a drastic worsening of the patient’s condition was observed on antifungal drugs. On day 38, panfungal PCR identified Pythium insidiosum, which is an aquatic organism belonging to the oomycete family. Based on the recent literature, this patient was promptly prescribed a systemic and local antibiotic regimen and cure was ultimately achieved. In order to facilitate P. insidiosum identification in future cases, we have generated the first matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) reference spectrum for P. insidiosum. It is planned to deposit this MALDI-TOF MS reference spectrum on an open-access platform and this should allow immediate identification of the pathogen. Finally, this case report also demonstrates that P. insidiosum is emerging outside tropical and subtropical areas. Clinicians and microbiologists should have better knowledge to accurately manage and diagnose this sight-threatening infection. Keywords: Pythiosis, Pythium insidiosum, Keratitis, Panfungal PCR, MALDI-TOF mass spectrometry
Published: 2019

19. Characterization of the novel HLA-C*01:214 allele by sequencing-based typing

Author: Judith Desoutter, Valentine Jacob, Nicolas Guillaume, and Céline Dard
Subjects: Genetics, Histocompatibility Testing, Immunology, Genes, MHC Class I, Nucleotide substitution, Human leukocyte antigen, Exons, HLA-C Antigens, Sequence Analysis, DNA, Biology, DNA sequencing, Exon, HLA-C, Immunology and Allergy, Humans, Typing, Allele, Alleles
Abstract: HLA-C*01:214 differs from HLA-C*01:02:01:01 by one nucleotide substitution in codon -10 in exon 1.
Published: 2021

20. A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: is it time to reconsider the current contraindication?

Author: Virgilio E. Failoc-Rojas, Carlos Chaccour, Pascal Del Giudice, Jaime Piquero-Casals, Menno R. Smit, Kevin C. Kobylinski, Georgina S. Humphreys, Kasia Stepniewska, Céline Dard, Sabine Specht, Wuelton Marcelo Monteiro, Franck Boralevi, Jean T. Coulibaly, Philippe J Guerin, Antoni Soriano-Arandes, Belen Pedrique, David Wimmersberger, Lucia Romani, Marimar Sáez-De-ocariz, Kalynn Kennon, Daniel T. Engelman, Virak Khieu, Anne Faisant, Michael Marks, Marie Pierre Brenier-Pinchart, Annabel Maruani, Andrew C Steer, Podjanee Jittamala, Lorenz von Seidlein, Oliver Sokana, Eli Harriss, Nicholas J. White, Jennifer Keiser, Institut Català de la Salut, [Jittamala P] Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. [Monteiro W] Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil. Universidade do Estado do Amazonas, Manaus, Brazil. [Smit MR] Amsterdam Centre for Global Child Health, Emma Children's Hospital, Amsterdam, The Netherlands. University Medical Centres, University of Amsterdam, Amsterdam, The Netherlands. Malaria Epidemiology Unit, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom. [Pedrique B, Specht S] Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland. [Chaccour CJ] ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain. Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique. Ifakara Health Institute, Ifakara, United Republic of Tanzania. Instituto de Medicina Tropical Universidad de Navarra, Pamplona, Spain. [Soriano-Arandes A] Unitat de Patologia Infecciosa i Immunodeficiències de Pediatria, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Centre Hospitalier de Basse-Terre [Guadeloupe], Centre Hospitalier Intercommunal Fréjus - St Raphaël (CHI Fréjus - St Raphaël), MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN), Centre Hospitalier Universitaire [Grenoble] (CHU), CHU Bordeaux [Bordeaux], General Paediatrics, APH - Global Health, Downs, Jennifer A., and Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques
Subjects: Pediatrics, Ectoparasitic Infections, [SDV]Life Sciences [q-bio], RC955-962, Helminthiasis, Administration, Oral, Onchocerciasis, Geographical locations, Antibiòtics macròlids - Ús terapèutic, Scabies, Families, Medical Conditions, 0302 clinical medicine, Ivermectin, Arctic medicine. Tropical medicine, Medicine and Health Sciences, compuestos orgánicos::lactonas::policétidos::macrólidos::ivermectina [COMPUESTOS QUÍMICOS Y DROGAS], 030212 general & internal medicine, Antibiòtics macròlids - Efectes secundaris, Children, Anthelmintics, Pediatria, wa_900, Neglected Diseases, qv_250, Research Assessment, 3. Good health, Europe, Infectious Diseases, Strongyloidiasis, Systematic review, terapéutica::contraindicaciones::contraindicaciones de los medicamentos [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Research Design, Helminth Infections, Child, Preschool, Meta-analysis, Other subheadings::Other subheadings::/administration & dosage [Other subheadings], France, Public aspects of medicine, RA1-1270, Research Article, Neglected Tropical Diseases, medicine.drug, wc_880, medicine.medical_specialty, wa_950, Systematic Reviews, Clinical Research Design, 030231 tropical medicine, Health Occupations::Medicine::Pediatrics [DISCIPLINES AND OCCUPATIONS], Sexually Transmitted Diseases, MEDLINE, Research and Analysis Methods, wa_110, 03 medical and health sciences, qx_200, Parasitic Diseases, medicine, Humans, European Union, Trichuriasis, Adverse effect, profesiones sanitarias::medicina::pediatría [DISCIPLINAS Y OCUPACIONES], ws_430, Otros calificadores::Otros calificadores::/administración & dosificación [Otros calificadores], business.industry, Body Weight, Public Health, Environmental and Occupational Health, Infant, Therapeutics::Contraindications::Contraindications, Drug [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Tropical Diseases, medicine.disease, Clinical trial, Soil-Transmitted Helminthiases, Age Groups, People and Places, Population Groupings, Adverse Events, business
Abstract: Background Oral ivermectin is a safe broad spectrum anthelminthic used for treating several neglected tropical diseases (NTDs). Currently, ivermectin use is contraindicated in children weighing less than 15 kg, restricting access to this drug for the treatment of NTDs. Here we provide an updated systematic review of the literature and we conducted an individual-level patient data (IPD) meta-analysis describing the safety of ivermectin in children weighing less than 15 kg. Methodology/Principal findings A systematic review was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) for IPD guidelines by searching MEDLINE via PubMed, Web of Science, Ovid Embase, LILACS, Cochrane Database of Systematic Reviews, TOXLINE for all clinical trials, case series, case reports, and database entries for reports on the use of ivermectin in children weighing less than 15 kg that were published between 1 January 1980 to 25 October 2019. The protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO): CRD42017056515. A total of 3,730 publications were identified, 97 were selected for potential inclusion, but only 17 sources describing 15 studies met the minimum criteria which consisted of known weights of children less than 15 kg linked to possible adverse events, and provided comprehensive IPD. A total of 1,088 children weighing less than 15 kg were administered oral ivermectin for one of the following indications: scabies, mass drug administration for scabies control, crusted scabies, cutaneous larva migrans, myiasis, pthiriasis, strongyloidiasis, trichuriasis, and parasitic disease of unknown origin. Overall a total of 1.4% (15/1,088) of children experienced 18 adverse events all of which were mild and self-limiting. No serious adverse events were reported. Conclusions/Significance Existing limited data suggest that oral ivermectin in children weighing less than 15 kilograms is safe. Data from well-designed clinical trials are needed to provide further assurance., Author summary Oral ivermectin is a safe and efficacious drug for the treatment of neglected tropical diseases. To date, ivermectin is not indicated in children weighing less than 15 kg because there have been insufficient safety data to support a change of recommendation. A PRISMA-level systematic review was conducted, and 97 potential sources were identified. All lead investigators were contacted to share individual patient data if they could provide the minimum criteria. These were the known weights of the children less than 15 kg in whom there were possible adverse events. A total of 17 investigators replied, sharing individual-level patient data (IPD) from 15 studies, which represent a database of 1,088 children weighing less than 15 kg treated with oral ivermectin. Overall 18 adverse events were reported in 1.4% (15/1,088) of children, all of which were mild and self-limiting. No serious adverse events were recorded. These data suggest that ivermectin is safe for use in children weighing less than 15 kilograms. Further data from well-designed clinical trials are needed to assess the safety of oral ivermectin at escalating doses in children weighing less than 15 kg.
Published: 2021

21. Characterization of the novel HLA-A*26:208 allele by sequencing-based typing

Author: Imad Oukasse, Céline Dard, Alexandre Walencik, Dominique Masson, and Béatrice Bardy
Subjects: Genetics, Human leucocyte antigen, HLA-A Antigens, Histocompatibility Testing, Immunology, High-Throughput Nucleotide Sequencing, Sequence Analysis, DNA, Biology, DNA sequencing, HLA-A, HLA Antigens, Immunology and Allergy, Humans, Typing, Allele, Alleles
Abstract: The novel HLA-A*26:208 allele was characterized using two next generation sequencing technologies.
Published: 2021

22. Characterization of the novel HLA-B*15:514 allele in a French hematopoietic stem cell donor

Author: Dominique Masson, Béatrice Bardy, Ornella Senoussi, Stéphane Buhler, and Céline Dard
Subjects: ddc:616, Human leucocyte antigen, Immunology, Hematopoietic stem cell, High-Throughput Nucleotide Sequencing, Human leukocyte antigen, Biology, Hematopoietic Stem Cells, Molecular biology, HLA-B, Tissue Donors, medicine.anatomical_structure, 514 [HLA-B*15], HLA-B Antigens, NGS, Genetics, medicine, 145 [HLA-C*02], Immunology and Allergy, Humans, Allele, Novel HLA allele, Alleles
Abstract: The novel HLA-B*15:514 allele was characterized using two next-generation sequencing technologies.
Published: 2020

23. Evaluation of ID Fungi Plates Medium for Identification of Molds by MALDI Biotyper

Author: Danièle Maubon, Thomas Girard, Céline Dard, Tahinamandranto Rasamoelina, Odile Cognet, Muriel Cornet, Charlotte Romero, Marie Gladys Robert, and Cécile Garnaud
Subjects: Microbiology (medical), Antifungal, food.ingredient, Hypha, Diagnostic Tests, Routine, medicine.drug_class, Extraction (chemistry), Fungi, Mycology, Direct transfer, Biology, Culture Media, food, Ascomycota, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, medicine, Humans, Agar, Food science, Subculture (biology), Microscopic morphology, Candida, Fungal material
Abstract: MALDI-TOF mass spectrometry (MS) identification of pathogenic filamentous fungi is often impaired by difficulties in harvesting hyphae embedded in the medium and long extraction protocols. The ID Fungi Plate (IDFP) is a novel culture method developed to address such difficulties and improve the identification of filamentous fungi by MALDI-TOF MS. We cultured 64 strains and 11 clinical samples on IDFP, Sabouraud agar-chloramphenicol (SAB), and ChromID Candida agar (CAN2). We then compared the three media for growth, ease of harvest, amount of material picked, and MALDI-TOF identification scores after either rapid direct transfer (DT) or a long ethanol-acetonitrile (EA) extraction protocol. Antifungal susceptibility testing and microscopic morphology after subculture on SAB and IDFP were also compared for ten molds. Growth rates and morphological aspects were similar for the three media. With IDFP, harvesting of fungal material for the extraction procedure was rapid and easy in 92.4% of cases, whereas it was tedious on SAB or CAN2 in 65.2% and 80.3% of cases, respectively. The proportion of scores above 1.7 (defined as acceptable identification) were comparable for both extraction protocols using IDFP (P = 0.256). Moreover, rates of acceptable identification after DT performed on IDFP (93.9%) were significantly higher than those obtained after EA extraction with SAB (69.7%) or CAN2 (71.2%) (P =
Published: 2020

24. Characterization of the novel HLA-C*02:185 allele in a kidney transplant recipient

Author: Ornella Senoussi, Céline Dard, Dominique Masson, Béatrice Bardy, and Vincent Elsermans
Subjects: Human leucocyte antigen, Histocompatibility Testing, Immunology, Nucleotide substitution, HLA-C Antigens, Sequence Analysis, DNA, Biology, Molecular biology, Kidney Transplantation, Kidney transplant recipient, HLA-C, Exon, Genetics, Immunology and Allergy, Humans, Allele, Alleles
Abstract: HLA-C*02:185 differs from HLA-C*02:02:02:01 by one nucleotide substitution at codon 180 in exon 3.
Published: 2020

25. Characterization of two novel HLA alleles, C03:03:58 and DQB106:288, in a French hematopoietic stem cell donor

Author: Céline, Dard, Ornella, Senoussi, Vincent, Elsermans, Béatrice, Bardy, and Dominique, Masson
Subjects: Histocompatibility Testing, HLA-DQ beta-Chains, High-Throughput Nucleotide Sequencing, Humans, Hematopoietic Stem Cells, Alleles, Tissue Donors
Abstract: Two novel HLA alleles were detected using two next generation sequencing technologies.
Published: 2020

26. A MORC-driven transcriptional switch controls Toxoplasma developmental trajectories and sexual commitment

Author: Yohann Couté, Dominique Cannella, Christopher Swale, Philippe Ortet, Fabien Sindikubwabo, Céline Dard, Lucid Belmudes, Alexandre Bougdour, Mohamed-Ali Hakimi, Mohamed Barakat, Dayana C. Farhat, Pieter-Jan De Bock, Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Laboratoire de parasitologie-mycologie, CHU Grenoble, Laboratoire Adaptation et pathogénie des micro-organismes [Grenoble] (LAPM), Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Laboratoire d'Ecologie Microbienne de la Rhizosphère et d'Environnements Extrêmes (LEMIRE), Institut de Biosciences et Biotechnologies d'Aix-Marseille (ex-IBEB) (BIAM), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Etude de la dynamique des protéomes (EDyP ), Laboratoire de Biologie à Grande Échelle (BGE - UMR S1038), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes (UGA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes (UGA), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), and ANR-18-CE15-0023,HostQuest,Stratégies de Persistence de Toxoplasma gondii : Conquérir la Cellule Hôte et Echapper à la Réponse Immune Innée(2018)
Subjects: Models, Molecular, Transcription, Genetic, [SDV]Life Sciences [q-bio], Protozoan Proteins, Antibodies, Protozoan, Applied Microbiology and Biotechnology, Protein Structure, Secondary, chromatin remodeling, Histones, microrchidia protein, Histone code, ComputingMilieux_MISCELLANEOUS, Adenosine Triphosphatases, Genetics, 0303 health sciences, Chromatin, Histone Code, Histone, Toxoplasma, epigenetic, Toxoplasmosis, Protein Binding, Microbiology (medical), Apetala 2, Primary Cell Culture, Immunology, Toxoplasma gondii, Biology, Microbiology, Histone Deacetylases, Article, 03 medical and health sciences, Animals, Humans, Epigenetics, Transcription factor, Gene, 030304 developmental biology, Life Cycle Stages, 030306 microbiology, Cell Biology, Fibroblasts, Cats, biology.protein, gene expression, sexual commitment, Histone deacetylase, Protein Processing, Post-Translational, Transcription Factors
Abstract: Toxoplasma gondii has a complex life cycle that is typified by asexual development that takes place in vertebrates, and sexual reproduction, which occurs exclusively in felids and is therefore less studied. The developmental transitions rely on changes in the patterns of gene expression, and recent studies have assigned roles for chromatin shapers, including histone modifications, in establishing specific epigenetic programs for each given stage. Here, we identified the T. gondii microrchidia (MORC) protein as an upstream transcriptional repressor of sexual commitment. MORC, in a complex with Apetala 2 (AP2) transcription factors, was shown to recruit the histone deacetylase HDAC3, thereby impeding the accessibility of chromatin at the genes that are exclusively expressed during sexual stages. We found that MORC-depleted cells underwent marked transcriptional changes, resulting in the expression of a specific repertoire of genes, and revealing a shift from asexual proliferation to sexual differentiation. MORC acts as a master regulator that directs the hierarchical expression of secondary AP2 transcription factors, and these transcription factors potentially contribute to the unidirectionality of the life cycle. Thus, MORC plays a cardinal role in the T. gondii life cycle, and its conditional depletion offers a method to study the sexual development of the parasite in vitro, and is proposed as an alternative to the requirement of T. gondii infections in cats.
Published: 2020

27. Identification of seven novel HLA-C alleles

Author: Béatrice Bardy, Dominique Masson, Céline Dard, Stéphane Buhler, and Ornella Senoussi
Subjects: ddc:616, Genetics, HLA-C, Histocompatibility Testing, Immunology, Genes, MHC Class I, High-Throughput Nucleotide Sequencing, HLA-C Antigens, Biology, NGS, Immunology and Allergy, Humans, Identification (biology), Allele, Novel HLA class I alleles, Alleles
Abstract: Seven novel HLA-C alleles were detected using two next-generation sequencing technologies.
Published: 2020

28. Characterization of the novel HLA-B*07:398 allele in a French hematopoietic stem cell donor

Author: Céline Dard, Ornella Senoussi, Stéphane Buhler, Béatrice Bardy, and Dominique Masson
Subjects: ddc:616, Base Sequence, Histocompatibility Testing, Immunology, Hematopoietic Stem Cell Transplantation, Sequence Analysis, DNA, Hematopoietic Stem Cells, HLA, HLA-B7 Antigen, 398 [HLA-B*07], NGS, Genetics, Immunology and Allergy, Novel HLA alleles, Sequence Alignment, Alleles
Abstract: HLA-B*07:398 differs from HLA-B*07:02:01:01 by one nucleotide substitution at codon 98.3 in exon 3.
Published: 2020

29. Chronic toxoplasmosis and sleepiness in obstructive sleep apnea: Is there a link?

Author: Jean-Louis Pépin, Marie Peeters, Renaud Tamisier, Céline Dard, Hélène Fricker-Hidalgo, Marie-Pierre Brenier-Pinchart, Sébastien Bailly, Hervé Pelloux, Laboratoire de parasitologie-mycologie, CHU Grenoble, Host-Pathogen Interactions and Immunity to Infection [Grenoble], Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Hypoxie : Physiopathologie Respiratoire et Cardiovasculaire (HP2), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA), and Bodescot, Myriam
Subjects: 0301 basic medicine, Male, Sleepiness, Pulmonology, Physiology, Apnea, Pathology and Laboratory Medicine, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Toxoplasma Gondii, Body Mass Index, 0302 clinical medicine, Interquartile range, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine and Health Sciences, 2. Zero hunger, Protozoans, Sleep disorder, Sleep Apnea, Obstructive, Multidisciplinary, Sleep apnea, Eukaryota, Middle Aged, 3. Good health, Serology, Neurology, Physiological Parameters, Toxoplasmosis, Cerebral, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine, Female, Sample collection, Toxoplasma, [SDV.MP.PAR] Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, Toxoplasmosis, Research Article, Adult, medicine.medical_specialty, Sleep Apnea, Science, 03 medical and health sciences, Internal medicine, medicine, Parasitic Diseases, Humans, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, Obesity, Protozoan Infections, business.industry, Body Weight, Case-control study, Organisms, Biology and Life Sciences, medicine.disease, Parasitic Protozoans, respiratory tract diseases, Obstructive sleep apnea, 030104 developmental biology, Immunoglobulin M, Case-Control Studies, Immunoglobulin G, Chronic Disease, [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, business, Sleep Disorders, Physiological Processes, Sleep, Body mass index, 030217 neurology & neurosurgery
Abstract: International audience; Introduction: Sleepiness is the main clinical expression of obstructive sleep apnea (OSA) syndrome resulting from upper airway collapse. Recent studies have discussed the fact that the presence of T. gondii cysts in the brain and the resulting biochemical and immunological mechanisms could be linked to neurobehavioral disorders. The aim of the present study was to explore the potential impact of chronic toxoplasmosis on sleepiness and on obstructive sleep apnea (OSA) severity in OSA obese patients.Materials and methods: A case control study on obese patients screened for OSA was performed. According to the sleep disorder and matched based on gender, age and body mass index (BMI), two groups of obese patients were selected from our sample collection database. All patients were tested for toxoplasmosis serological status measuring anti-Toxoplasma IgG and IgM levels. Univariable and multivariable logistic regression models were performed to assess the impact of chronic toxoplasmosis on sleepiness and OSA severity.Results: 107 obese patients suffering from OSA were included in the study (median age: 53.3 years Interquartile range (IQR): [41.9-59.9]; median BMI: 39.4 kg/m2 IQR: [35.5-44.1], apnea-hypopnea index = 27.5 events/h [10.7-49.9]). Chronic toxoplasmosis was present in 63.4% and 70.7% of patients with or without sleepiness (p = 0.48), respectively and was not associated either to sleepiness (OR: 0.76, 95% CI: [0.52; 2.33], p = 0.64) or OSA severity (OR = 1.75, 95% CI: [0.51; 5.98] p = 0.37).Conclusion: Although chronic Toxoplasma infection in immunocompetent humans has been associated to several behavioral disorders or pathologies in recent literature, we demonstrate here that chronic toxoplasmosis is not associated to sleepiness and to sleep apnea syndrome severity in obese patients suspected of sleep apnea syndrome.
Published: 2020

30. Identification of four novel HLA-A alleles

Author: Ornella Senoussi, Béatrice Bardy, Céline Dard, Dominique Masson, and Stéphane Buhler
Subjects: Genetics, ddc:616, HLA-A, HLA-A Antigens, Histocompatibility Testing, Immunology, High-Throughput Nucleotide Sequencing, Biology, HLA Antigens, NGS, Humans, Immunology and Allergy, Identification (biology), Allele, Novel HLA class I alleles, Alleles
Abstract: Four novel HLA-A alleles were detected using two next-generation sequencing technologies.
Published: 2020

31. Profile of GenMark’s ePlex® blood culture identification fungal pathogen panel

Author: Danièle Maubon, Muriel Cornet, Cécile Garnaud, Céline Dard, Thérapeutique Recombinante Expérimentale (TIMC-IMAG-TheREx), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Laboratoire de parasitologie-mycologie, and CHU Grenoble
Subjects: 0301 basic medicine, medicine.medical_specialty, antifungal stewardship, diagnosis, 030106 microbiology, Context (language use), invasive fungal infection, blood culture, Pathology and Forensic Medicine, Sepsis, 03 medical and health sciences, Health care, Genetics, Humans, Medicine, Blood culture, Intensive care medicine, Molecular Biology, [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, Fungemia, medicine.diagnostic_test, business.industry, candidemia, Fungi, Reproducibility of Results, molecular diagnostic, Fungal pathogen, medicine.disease, 3. Good health, PCR, Molecular Diagnostic Techniques, Mycoses, Molecular Medicine, Identification (biology), Reagent Kits, Diagnostic, Stewardship, business
Abstract: International audience; Fungemia presents high morbi-mortality and thus rapid microbiological diagnosis may contribute to appropriate patient management. In the last decade, kits based on molecular technologies have become available and health care institutes are increasingly facing critical investment choices. Although all these tools aim to achieve rapid fungal detection and species identification, they display different inherent characteristics. Areas covered: Considering technologies allowing detection and identification of fungal species in a sepsis context, the market proposes either tests on positive blood culture or tests on patient's whole blood. In this review, the authors describe and compare the ePlex® Blood Culture Identification Fungal Pathogen (BCID-FP) test, a fully automated one-step single-use cartridge assay that has been designed to detect identify frequent or rare but emerging, fungal species, from positive blood culture. A comparison with the competing kits is provided. Expert commentaries: The ePlex BCID-FP test provides a diversified and rather relevant panel. Its easy-to-use cartridges allow flexible use around the clock. Nevertheless, prospective clinical studies assessing the time-to-result benefit on antifungal stewardship and on hospital length of stay are not available yet. New tools aim to benefit clinicians and patients, but they should be accompanied by supervision of result interpretation and adaptation of antifungal stewardship.
Published: 2017

32. Late diagnosis of congenital toxoplasmosis based on serological follow-up: A case report

Author: Hervé Pelloux, Cathy Chemla, Isabelle Villena, Alexandre Mzabi, Marie Baret, Hélène Fricker-Hidalgo, Céline Dard, Marie-Pierre Brenier-Pinchart, Centre Hospitalier Universitaire [Grenoble] (CHU), Centre Hospitalier Universitaire de Reims (CHU Reims), Protozooses Transmises par l'Alimentation (Cryptosporidiose, Giardose et Toxoplasmose) : Mode de Contamination et Pathogénie (PROTAL) - EA 3800 (PROTAL), Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), and Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)
Subjects: Adult, 0301 basic medicine, Pediatrics, medicine.medical_specialty, Delayed Diagnosis, 030231 tropical medicine, 030106 microbiology, Population, Antibodies, Protozoan, Enzyme-Linked Immunosorbent Assay, Toxoplasmosis, Congenital, Serology, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Pregnancy, Humans, Medicine, Serologic Tests, education, ComputingMilieux_MISCELLANEOUS, Subclinical infection, [SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health, education.field_of_study, biology, business.industry, Infant, Newborn, Chorioretinitis, Infant, Toxoplasma gondii, biology.organism_classification, medicine.disease, Toxoplasmosis, Congenital toxoplasmosis, Immunoglobulin A, 3. Good health, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Infectious Diseases, Immunoglobulin M, Immunoglobulin G, Pregnancy Complications, Parasitic, Immunology, Female, Parasitology, business, Toxoplasma, Follow-Up Studies
Abstract: Toxoplasma gondii is a protozoan parasite infecting up to one third of the world's population. T. gondii infection is usually benign in immunocompetent patients but can be life-threatening when congenitally transmitted. Congenital toxoplasmosis presentation ranges from severe central nervous system and ocular features, to a well appearing newborn with onset of complications late in childhood. The diagnosis of subclinical form remains important since early treatment reduces later complications such as chorioretinitis. We report an atypical case of congenital toxoplasmosis with a delayed diagnosis, based on Toxoplasma-specific serological follow-up. The infant was born to a mother who became infected during pregnancy, thus inducing infant biological and clinical follow-up. Neither biological nor clinical arguments favored a diagnosis of congenital toxoplasmosis until ten months of life. Congenital toxoplasmosis was then suspected because of an unusual increase of specific IgG levels. Diagnosis was confirmed by detection of newly synthesized newborn Ig isotypes using complementary comparative mother-to-child immunological profile techniques and specific treatment therefore administered. This report highlights the importance to follow up newborns at risk of congenital toxoplasmosis with specific and newborn-appropriate techniques until Toxoplasma-IgG titers are completely negative. This allows not only the exclusion of congenital toxoplasmosis when serology becomes negative, but also the diagnosis and treatment of congenital toxoplasmosis when infection is detected later in development.
Published: 2017

33. First Evidence of Angiostrongyliasis Caused by Angiostrongylus cantonensis in Guadeloupe, Lesser Antilles

Author: Céline Dard, Dorothée Harrois, Yvonne Qvarnstrom, LeAnne M. Fox, Jean-Eudes Piloquet, Helmi M'kada, Didier Mattera, and Jean-Christophe Hebert
Subjects: 0301 basic medicine, Pathology, medicine.medical_specialty, High prevalence, Eosinophilic Meningitis, Cerebral Spinal Fluid, 030231 tropical medicine, 030106 microbiology, Biology, biology.organism_classification, medicine.disease, Virology, Pacific basin, Angiostrongylus cantonensis, 03 medical and health sciences, 0302 clinical medicine, Infectious Diseases, Ivermectin, medicine, Angiostrongyliasis, Parasitology, Lungworm, medicine.drug
Abstract: Infection by the rat lungworm Angiostrongylus cantonensis represents the most common cause of infectious eosinophilic meningitis in humans, causing central nervous system (CNS) angiostrongyliasis. Most of CNS angiostrongyliasis cases were described in Asia, Pacific Basin, Australia, and some limited parts of Africa and America. CNS angiostrongyliasis has been reported in the Caribbean but never in the Lesser Antilles. The primary objectives of this study were to depict the first case of CNS angiostrongyliasis in the Lesser Antilles and investigate the environmental presence of A. cantonensis in Guadeloupe, Lesser Antilles. In December 2013, a suspected case of CNS angiostrongyliasis in an 8-month-old infant in Guadeloupe was investigated by real-time polymerase chain reaction (PCR) testing on cerebral spinal fluid (CSF). The environmental investigation was performed by collecting Achatina fulica molluscs from different parts of Guadeloupe and testing the occurrence of A. cantonensis by real-time PCR. CSF from the suspected case of angiostrongyliasis was positive for A. cantonensis by real-time PCR. Among 34 collected snails for environmental investigation, 32.4% were positive for A. cantonensis. In conclusion, we report the first laboratory-confirmed case of CNS-angiostrongyliasis in the Lesser Antilles. We identified the presence and high prevalence of A. cantonensis in A. fulica in Guadeloupe. These results highlight the need to increase awareness of this disease and implement public health programs in the region to prevent human cases of angiostrongyliasis and improve management of eosinophilic meningitis patients.
Published: 2017

34. Characterization of the novel <scp> HLA‐DQB1*03:01:46 </scp> variant allele in a French hematopoietic stem cell donor

Author: Béatrice Bardy, Sylvie Ferrari-Lacraz, Ornella Senoussi, Dominique Masson, and Céline Dard
Subjects: musculoskeletal diseases, Human leucocyte antigen, HLA-DQB1, Base Sequence, endocrine system diseases, Histocompatibility Testing, Immunology, nutritional and metabolic diseases, Hematopoietic stem cell, Nucleotide substitution, Variant allele, Biology, Hematopoietic Stem Cells, Molecular biology, Exon, medicine.anatomical_structure, immune system diseases, Genetics, medicine, HLA-DQ beta-Chains, Immunology and Allergy, skin and connective tissue diseases, Alleles
Abstract: HLA-DQB1*03:01:46 differs from HLA-DQB1*03:01:01:01 by one nucleotide substitution at codon 142.3 in exon 3.
Published: 2020

35. Characterization of the novel <scp> HLA‐DRB1*15:170 </scp> allele in a French hematopoietic stem cell donor

Author: Céline Dard, Ornella Senoussi, Vincent Elsermans, Béatrice Bardy, and Dominique Masson
Subjects: Base Sequence, Histocompatibility Testing, Immunology, Hematopoietic Stem Cell Transplantation, Genetics, Immunology and Allergy, Sequence Analysis, DNA, Hematopoietic Stem Cells, Sequence Alignment, Alleles, HLA-DRB1 Chains
Abstract: HLA-DRB1*15:170 differs from HLA-DRB1*15:01:01:03 by one nucleotide substitution at codon 85 in exon 2.
Published: 2020

36. Angiostrongylus cantonensis Infection of Central Nervous System, Guiana Shield

Author: Emma Cuadro-Alvarez, Elise Martin, Loïc Epelboin, Antoine Defo, Céline Dard, Annabelle Brunelin, Dorothée Harrois, Yvonne Qvarnstrom, Narcisse Elenga, Falucar Njuieyon, Magalie Demar, Yajaira Mrsic, Fanny Henaff, Denis Blanchet, Nicole Desbois-Nogard, Noémie Lachaume, Chimène Maniassom, Service de Pédiatrie [Cayenne, Guyanne Française], Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Groupe d'histoire et diffusion des sciences d'Orsay (GHDSO), Université Paris-Sud - Paris 11 (UP11), Unité des Maladies Infectieuses et Tropicales (UMIT), Université de Guyane (UG), Laboratoire de Biologie Médicale [CH Basse-Terre, Guadeloupe], Centre Hospitalier de Basse-Terre [Guadeloupe], Laboratoire de Microbiologie, CHU Pointe-à-Pitre/Abymes [Guadeloupe], Department of parasitic diseases, Centers for Disease Control, Medicine Department, Ecosystemes Amazoniens et Pathologie Tropicale (EPat), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Guyane (UG)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Guyane (UG), Laboratoire de parasitologie-mycologie, CHU Grenoble, EA 3593 Université des Antilles et de la Guyane, Service de Pédiatrie, and Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]
Subjects: Microbiology (medical), Pathology, medicine.medical_specialty, Eosinophilic Meningitis, Epidemiology, Central nervous system, 030231 tropical medicine, lcsh:Medicine, parasites, Angiostrongylus cantonensis infection, Transverse myelitis, Serology, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, Cerebrospinal fluid, 0302 clinical medicine, transverse myelitis, eosinophilic meningitis, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, parasitic diseases, medicine, lcsh:RC109-216, 030212 general & internal medicine, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, biology, business.industry, lcsh:R, Angiostrongylus cantonensis, medicine.disease, biology.organism_classification, 3. Good health, medicine.anatomical_structure, Infectious Diseases, Guiana Shield, nematodes, Angiostrongyliasis, meningitis/encephalitis, business
Abstract: International audience; We report a case of eosinophilic meningitis complicated by transverse myelitis caused by Angiostrongylus cantonensis in a 10-year-old boy from Brazil who had traveled to Suriname. We confirmed diagnosis by serology and real-time PCR in the cerebrospinal fluid. The medical community should be aware of angiostrongyliasis in the Guiana Shield.
Published: 2018

37. Relevance of and New Developments in Serology for Toxoplasmosis

Author: Hélène Fricker-Hidalgo, Hervé Pelloux, Céline Dard, and Marie-Pierre Brenier-Pinchart
Subjects: 0301 basic medicine, medicine.medical_specialty, 030106 microbiology, Antibodies, Protozoan, Toxoplasma gondii, Biology, medicine.disease, biology.organism_classification, Toxoplasmosis, Serology, Diagnosis, Differential, 03 medical and health sciences, Infectious Diseases, Parasitic disease, Immunology, Epidemiology, medicine, Animals, Humans, Relevance (law), Serologic Tests, Parasitology, Toxoplasma, Human Pathology
Abstract: Toxoplasmosis is a widespread parasitic disease caused by the intracellular parasite Toxoplasma gondii with a wide spectrum of clinical outcomes. The biological diagnosis of toxoplasmosis is often difficult and of paramount importance because clinical features are not sufficient to discriminate between toxoplasmosis and other illnesses. Serological tests are the most widely used biological tools for the diagnosis of toxoplasmosis worldwide. This review focuses on the crucial role of serology in providing answers to the most important questions related to the epidemiology and diagnosis of toxoplasmosis in human pathology. Notwithstanding their undeniable importance, serological tools need to be continuously improved and the interpretation of the ensuing results remains complex in many circumstances.
Published: 2016

38. How to estimate time of infection with Toxoplasma gondii in pregnant women. Use of specific IgG and IgM kinetics by 7 techniques on 691 sera

Author: Cécile Garnaud, Hervé Pelloux, Hélène Fricker-Hidalgo, Anne-Laure Coston, Dominique Jean, Sébastien Bailly, Céline Dard, and Marie-Pierre Brenier-Pinchart
Subjects: Adult, 0301 basic medicine, Microbiology (medical), Time Factors, Igm antibody, 030106 microbiology, Antibody Affinity, Antibodies, Protozoan, Serology, 03 medical and health sciences, 0302 clinical medicine, Pregnancy, parasitic diseases, Humans, Medicine, Serologic Tests, 030212 general & internal medicine, Fluorescent Antibody Technique, Indirect, Retrospective Studies, biology, business.industry, Toxoplasma gondii, General Medicine, Specific igg, biology.organism_classification, Congenital toxoplasmosis, Kinetics, Titer, Infectious Diseases, Immunoglobulin M, Immunoglobulin G, Pregnancy Complications, Parasitic, Acute Disease, Chronic Disease, Immunology, biology.protein, Female, Indirect Immunofluorescence Assays, Pregnant Women, Antibody, business, Toxoplasma, Toxoplasmosis
Abstract: A difficulty when detecting both anti-Toxoplasma gondii–specific IgG and IgM in pregnant women is estimating the date of infection. The aim of this study was to compare the anti-Toxoplasma–specific immunoglobulin kinetics of 7 serological techniques to date the infection and to draw kinetic curves that are easy to use on a daily basis. IgG and IgM antibodies were measured on 691 sera samples. IgM appeared a few days, less than 1 week, after the beginning of the infection. Then, the levels of IgM reached a peak at approximately 3, 4, and 5 weeks with Toxo-ISAGA® IgM, IgM homemade indirect immunofluorescence assays, and Vidas Toxo® IgM, respectively. Furthermore, the Architect Toxo® IgG titers were higher than those of the Vidas Toxo® IgG results in recent infection (less than 6 months). This study provides new average IgM and IgG curves that can help to determine the approximate date of infection.
Published: 2020

39. First cases of Angiostrongylus cantonensis infection reported in Martinique, 2002–2017

Author: Nicole Desbois-Nogard, Eve Tessier, Christopher Swale, Katia de Meuron, André Cabié, Dorothée Harrois, Loïc Epelboin, Charline Miossec, Céline Dard, D.T. Nguyen, Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique], University of Kyonggi, Ecosystemes Amazoniens et Pathologie Tropicale (EPat), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Guyane (UG), Université Grenoble Alpes (COMUE) (UGA), Maladies infectieuses et tropicales dans la Caraïbe (MAITC EA 4537), CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de la Martinique [Fort de France]-Université des Antilles (UA), Laboratoire de Parasitologie-Mycologie-Sérologies Bactériennes et Parasitaires [CHU de la Martinique], and Centre Hospitalier Universitaire de la Martinique - CHU Martinique
Subjects: Male, Pediatrics, medicine.medical_specialty, Eosinophilic Meningitis, [SDV]Life Sciences [q-bio], Veterinary (miscellaneous), 030231 tropical medicine, Biology, lcsh:Infectious and parasitic diseases, 030308 mycology & parasitology, 03 medical and health sciences, Fatal Outcome, 0302 clinical medicine, Eosinophilia, Helminth, medicine, Animals, Humans, lcsh:RC109-216, Martinique, Meningitis, Serologic Tests, Child, Retrospective Studies, Strongylida Infections, Anthelmintics, Caribbean, 0303 health sciences, Caribbean island, Angiostrongylus cantonensis, Infant, Middle Aged, medicine.disease, biology.organism_classification, 3. Good health, Infectious Diseases, Insect Science, Parasitic disease, Angiostrongyliasis, Encephalitis, Female, Animal Science and Zoology, Parasitology, Research Article
Abstract: Neuroangiostrongyliasis is a parasitic disease caused by the accidental ingestion of the nematode Angiostrongylus cantonensis in its larval form. Human infection can lead to eosinophilic meningitis, sometimes complicated by life-threatening radiculomyelitis or encephalitis. Although some cases have been reported from other Caribbean Islands, no cases have been diagnosed in Martinique so far. Here, we report the first eight laboratory-confirmed cases of neuroangiostrongyliasis on the island of Martinique, French West Indies, between 1 January 2002 and 31 December 2017. One case was fatal and five resulted in neurological sequelae. The medical community should consider the risk of A. cantonensis infection in patients living in or returning from Martinique.Premiers cas d’angiostrongylose à Angiostrongylus cantonensis à la Martinique, de 2002 à 2017.L’angiostrongylose neuroméningée est une maladie parasitaire causée par l’ingestion accidentelle du nématode Angiostrongylus cantonensis sous sa forme larvaire. L’infection humaine peut conduire à une méningite à éosinophiles, pouvant évoluer en radiculomyélite ou encéphalite menaçant le pronostic vital. Bien que des cas aient été rapportés dans d’autres îles des Caraïbes, aucun cas n’avait été diagnostiqué à la Martinique jusqu’à présent. Dans cet article, nous caractérisons les huit premiers cas d’angiostrongylose neuroméningée biologiquement diagnostiqués à la Martinique, Antilles françaises, entre le 1
Published: 2020

40. Management of toxoplasmosis in transplant recipients: an update

Author: Cécile Garnaud, Hervé Pelloux, Hélène Fricker-Hidalgo, Christelle Pomares, Céline Dard, Marie-Pierre Brenier-Pinchart, and Pierre Marty
Subjects: 0301 basic medicine, Microbiology (medical), 030106 microbiology, Antiprotozoal Agents, Microbiology, 03 medical and health sciences, Immunocompromised Host, Risk Factors, Virology, Medicine, Animals, Humans, biology, business.industry, Hematopoietic Stem Cell Transplantation, Toxoplasma gondii, Hematopoietic stem cell, Organ Transplantation, biology.organism_classification, medicine.disease, Toxoplasmosis, Transplant Recipients, surgical procedures, operative, 030104 developmental biology, Infectious Diseases, medicine.anatomical_structure, Parasitic disease, Immunology, Solid organ transplantation, business, Toxoplasma, Immunosuppressive Agents
Abstract: Toxoplasmosis is a life-threatening parasitic disease for hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients. The risk of toxoplasmosis in transplant patients mainly depends on the degree of immunosuppression, the tropism of Toxoplasma gondii for the grafted tissue, and the seroprevalence in the general population. Although transplant recipients with toxoplasmosis have a high mortality rate, there are neither well-defined recommendations nor a consensus for the management of this disease in these patients. Areas covered. This review focuses on the management of toxoplasmosis in transplant recipients and discusses the various strategies for diagnosis, prevention, treatment, and follow-up in clinical practice. The literature search was conducted on publications in English and French using the search terms 'Toxoplasma gondii,' 'organ transplant,' and 'transplant recipients.' Expert commentary. The diagnosis of toxoplasmosis has greatly improved over the last two decades, but it is still a fatal illness. Non-specificity of the symptoms, resulting in a delay before diagnosis, and therapeutic failure are the main causes of death. The development of active treatments against cysts is one of the current challenges that will considerably improve the management of toxoplasmosis in transplant recipients by clearing chronic infection to avoid T. gondii reactivation.
Published: 2018

41. Uncommon and fatal case of cystoisosporiasis in a non HIV-immunosuppressed patient from a non-endemic country

Author: Lucie Post, Annick Bosseray, Hervé Pelloux, Cécile Garnaud, Danièle Maubon, Catherine Mansard, and Céline Dard
Subjects: Diarrhea, Pediatrics, medicine.medical_specialty, Acute decompensated heart failure, 030231 tropical medicine, Isosporiasis, 03 medical and health sciences, Feces, Immunocompromised Host, 0302 clinical medicine, Fatal Outcome, Acquired immunodeficiency syndrome (AIDS), Food Parasitology, Cystoisosporiasis, Communicable Diseases, Imported, Trimethoprim, Sulfamethoxazole Drug Combination, Medicine, Humans, Aged, biology, Isospora, business.industry, Transmission (medicine), Oocysts, medicine.disease, biology.organism_classification, Infectious Diseases, Methotrexate, Immunology, Coccidiostats, 030211 gastroenterology & hepatology, Parasitology, Cystoisospora belli, Female, France, medicine.symptom, business, Immunosuppressive Agents
Abstract: Cystoisospora belli (previously known as Isospora belli) is a tropical coccidian parasite sometimes leading to severe diarrhea in immunocompromised patients. Here we describe a fatal case of cystoisosporiasis in a non HIV-immunocompromised 71-year-old female with no recent travel history. Infection was either latent or potentially caused by the consumption of contaminated imported food from Asia. Diagnosis was made by microscopical detection of numerous C. belli oocysts in stools without specific staining. Treatment with TMP-SMZ slightly improved diarrhea within 3days, but dehydration subsequently led to acute decompensated heart failure and a fatal evolution. This report illustrates the possibility of severe cystoisosporiasis in non HIV-immunocompromised patients in a non-endemic country and highlights the risk of transmission through imported contaminated food consumption.
Published: 2017

42. Impact of heat-inactivation on anti-Toxoplasma IgM antibody levels

Author: Céline Dard, Marie-Pierre Brenier-Pinchart, Hélène Fricker-Hidalgo, and Hervé Pelloux
Subjects: 0301 basic medicine, Hot Temperature, business.industry, Igm antibody, 030106 microbiology, Biochemistry (medical), Clinical Biochemistry, General Medicine, medicine.disease, Toxoplasmosis, Microbiology, Heat inactivation, 03 medical and health sciences, 030104 developmental biology, Immunoglobulin M, Humans, Medicine, business, Toxoplasma
Published: 2017

43. Long-term sera storage does not significantly modify the interpretation of toxoplasmosis serologies

Author: Thibault Drouet, Hervé Pelloux, Hélène Fricker-Hidalgo, Sébastien Bailly, Céline Dard, and Marie-Pierre Brenier-Pinchart
Subjects: 0301 basic medicine, Microbiology (medical), Quality Control, Time Factors, 030106 microbiology, Antibodies, Protozoan, Subgroup analysis, Enzyme-Linked Immunosorbent Assay, Microbiology, Serology, 03 medical and health sciences, medicine, Humans, Serologic Tests, Molecular Biology, biology, Repeated measures design, Toxoplasma gondii, biology.organism_classification, medicine.disease, Toxoplasmosis, Cold Temperature, 030104 developmental biology, Immunoglobulin M, Immunoglobulin G, Immunology, Blood Banks, Female, Toxoplasma
Abstract: Background Serological investigation of Toxoplasma gondii can answer many questions about toxoplasmosis in human pathology. Along these lines, studies on serum storage in biobanks need to be performed especially in terms of determining the impact of storage on relevance of sera analysis after freezing. This study assessed the impact of long-term sera storage on the stability of anti-Toxoplasma immunoglobulins. Material and methods The stability of anti-Toxoplasma IgG and IgM was studied in 244 and 242 sera respectively, stored at − 20 °C from one month to ten years. ELISA-immunoassay (Vidas®, bioMerieux) was used for initial and post-storage analyses. Linear models for repeated measures and subgroup analyses were performed to assess the effect of storage duration and sample characteristics on immunoglobulins stability. Results Until ten years, the variability attributed to storage (maximum 8.07% for IgG, 13.17% for IgM) was below the variations inherent to the serological technique and allowed by quality assurance systems (15%). Subgroup analysis reported no variation attributed to sera storage. Serological interpretation was modified for 3 sera (1.2%) tested for IgM, all stored more than seven years. Conclusion Anti-Toxoplasma immunoglobulins can reliably be measured for at least up to six years of storage with no modification of interpretation of toxoplasmosis serologies.
Published: 2016

44. Interpretation of the Elecsys Toxo IgG avidity results for very low and very high index: study on 741 sera with a determined date of toxoplasmosis

Author: Luc Paris, Céline Dard, Coralie L'Ollivier, Renaud Piarroux, Sébastien Imbert, Hélène Fricker-Hidalgo, Hervé Pelloux, Sébastien Bailly, and C Bosson
Subjects: 0301 basic medicine, Microbiology (medical), Time Factors, High index, 030106 microbiology, Antibody Affinity, Antibodies, Protozoan, chemical and pharmacologic phenomena, Immunoglobulin G, 03 medical and health sciences, 0302 clinical medicine, Pregnancy, medicine, Humans, Avidity, 030212 general & internal medicine, Immunoassay, biology, medicine.diagnostic_test, business.industry, Spiramycin, General Medicine, Igg avidity, medicine.disease, Toxoplasmosis, Infectious Diseases, Immunology, biology.protein, Female, Antibody, business, medicine.drug
Abstract: Initial results with the Elecsys Toxo IgG Avidity assay showed some potential for interpretation of a very low or very high index result. We aimed to examine these new insights into interpretation using a large panel of serum samples and to define the optimal thresholds. A total of 741 patient serum samples with known date of infection (from a few weeks to more than 9 months after infection), were analysed with the Elecsys Toxo IgG Avidity assay. Values ≥80% (threshold defined by the manufacturer) were reported in 289 sera; 288 sera were sampled more than 4 months after infection. Thus, avidity values ≥80% excluded an infection less than 4 months. Avidity values ≥90% were reported in 112 sera sampled more than 9 months after infection. Thus, avidity values ≥90% excluded infection less than 9 months. Moreover avidity values ≤15% were reported in the 62 sera sampled less than 3 months after infection. Thus avidity values ≤15% excluded infection more than 3 months.
Published: 2016

45. Manifestations cliniques de l’angiostrongylose humaine en Martinique (2000–2017)

Author: Charline Miossec, K. de Meuron, N. Desbois, Benoît Rozé, Céline Dard, J. Pasquier, E. Tessier, André Cabié, and D.T. Nguyen
Subjects: Infectious Diseases
Abstract: Introduction L’angiostrongylose humaine est une zoonose transmise par un nematode du genre Angiostrongylus. Les 2 principales especes pathogenes identifiees chez l’Homme sont Angiostrongylus cantonensis ( A. cantonensis ) et Angiostrongylus costaricensis ( A. costaricensis ) responsables respectivement d‘angiostrongylose nerveuse (meningo-encephalite a eosinophiles) et d’angiostrongylose intestinale (pseudo-appendicite aigue avec hypereosinophilie). Cette pathologie est endemique sur le continent asiatique et en ocean pacifique mais reste peu decrite dans la Caraibe. La presence conjointe de ces 2 especes d’ Angiostrongylus dans un meme ecosysteme est exceptionnelle et n’a jamais ete rapportee, a notre connaissance, dans les petites Antilles. L’objectif de cette etude etait donc de decrire les donnees epidemiologiques sur l’angiostrongylose humaine en Martinique. Materiels et methodes Une etude observationnelle retrospective monocentrique a ete menee dans notre centre hospitalier entre le 01/01/2000 et le 31/12/2017. Tout patient ayant un diagnostic parasitologique (serologie ou PCR) ou anatomo-pathologique confirme d’angiostrongylose nerveuse ou intestinale etait inclus. Resultats Douze cas de d’angiostrongylose humaine ont ete identifies dans notre etude, incluant 8 cas d’angiostrongylose nerveuse a A. cantonensis et 4 cas d’angiostrongylose intestinale a A. costaricensis . L’âge median etait de 14 ans (IQR : 1–27) avec un sex-ratio homme/femme de 2. Une fievre (> 38 °C) etait observee dans 92 % des cas (11/12). Tous les patients presentaient une hypereosinophilie (> 0,5 G/L) avec une duree mediane de persistance de l’eosinophilie de 23,5 jours (IQR : 14,5–34,5). Tous les patients avaient une confirmation diagnostique serologique (sang ou LCR) ou anatomopathologique pour les cas d’ A. costaricensis . Le mode de transmission probable etait l’ingestion ou un contact etroit dans l’environnement avec Achatina fulica (hote intermediaire) dans 83 % des cas (10/12). Onze patients ont recu un traitement par albendazole (10/12) ou ivermectine (1/12). L’evolution etait favorable dans 11 cas sur 12. Un deces d’angiostrongylose neurologique a ete observe. Conclusion Nous decrivons la plus grande serie de cas d’angiostrongylose humaine dans la Caraibe. L’angiostrongylose, pathologie negligee, doit cependant etre evoquee devant toute hypereosinophilie avec atteinte neurologique ou abdominale en Martinique. Une meilleure connaissance de son hote intermediaire, Achatina fulica , devrait permettre d’ameliorer les strategies de prevention primaire et secondaire.
Published: 2018

46. Comparison of the Vidas System and Two Recent Fully Automated Assays for Diagnosis and Follow-Up of Toxoplasmosis in Pregnant Women and Newborns

Author: Hervé Pelloux, Marie-Laure Dardé, Jean-Benjamin Murat, Céline Dard, Marie-Pierre Brenier-Pinchart, Hélène Fricker Hidalgo, Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre National de Référence (CNR) Toxoplasmose/Toxoplasma Biological Resource Center (BRC) (CNR Toxoplasmose-Toxoplasma BRC), CHU Limoges, Université de Limoges (UNILIM), Neuroépidémiologie Tropicale (NET), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire Adaptation et pathogénie des micro-organismes [Grenoble] (LAPM), Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Centre National de Référence (CNR) Toxoplasmose/Toxoplasma Biological Resource Center (BRC) ( CNR Toxoplasmose-Toxoplasma BRC ), Université de Limoges ( UNILIM ), Neuroépidémiologie Tropicale ( NET ), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST ), Université de Limoges ( UNILIM ) -Université de Limoges ( UNILIM ), Laboratoire Adaptation et pathogénie des micro-organismes [Grenoble] ( LAPM ), and Université Joseph Fourier - Grenoble 1 ( UJF ) -Centre National de la Recherche Scientifique ( CNRS )
Subjects: Microbiology (medical), Adult, medicine.medical_specialty, Clinical Biochemistry, Immunology, Antibodies, Protozoan, Immunologic Tests, Sensitivity and Specificity, Immunoglobulin G, Serology, 03 medical and health sciences, Young Adult, Pregnancy, Diagnostic Laboratory Immunology, parasitic diseases, Immunology and Allergy, Medicine, Humans, Avidity, Seroconversion, Pregnancy Complications, Infectious, 030304 developmental biology, Automation, Laboratory, 0303 health sciences, biology, 030306 microbiology, business.industry, Obstetrics, Clinical Laboratory Techniques, Infant, Newborn, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, Igg avidity, medicine.disease, Toxoplasmosis, 3. Good health, Fully automated, Immunoglobulin M, biology.protein, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Female, Parasitology, business, Toxoplasma
Abstract: Serological testing to detect toxoplasmosis is of major importance to avoid the possible effects of the disease in newborns. This study assessed anti- Toxoplasma IgG and IgM with the Vidas (bioMérieux), Architect (Abbott), and Liaison (DiaSorin) systems in 631 sera from pregnant women and newborns as well as anti- Toxoplasma IgG avidity with these three systems on 54 sera from pregnant women with positive IgG and IgM. The IgG and IgM results were in agreement in, respectively, 95.2% and 98.3% (Vidas versus Architect) and 96.9% and 95.3% (Vidas versus Liaison) of the samples. Specificities were excellent for all the assays, while Vidas sensitivities ranged (depending on the classification of gray zone results) from 93.8 to 98.4% for IgG (Architect, 84.4 to 93.8%; Liaison, 93.8%) and from 81.8 to 90.9% for IgM (Architect, 63.6%; Liaison, 81.8 to 90.9%). In seroconversion sequences, IgMs were generally detected simultaneously by the three assays, while Architect was the earliest assay to detect IgG. In noninfected children, maternally transmitted IgGs were detected for a longer time with Architect than with the other systems. IgMs were positive in only one infected child with the Vidas and Liaison systems. Significantly more sera were classified in the high-avidity category with Vidas than with Architect. This evaluation shows similar performances for Vidas and more recent systems. The Vidas system adequately detects toxoplasmosis in pregnant women and newborns. This system fits the needs of laboratories working on small routine series for first-line testing as well as expert laboratories, due to a high specificity and a powerful avidity test.
Published: 2013

47. Pythiosis: Case report leading to new features in clinical and diagnostic management of this fungal-like infection

Author: Diane Bernheim, Damien Dupont, Florent Aptel, Celine Dard, Christophe Chiquet, Anne Cécile Normand, Renaud Piarroux, Muriel Cornet, and Danièle Maubon
Subjects: Infectious and parasitic diseases, RC109-216
Abstract: A 21-year-old man developed infectious keratitis after swimming in Spain whilst wearing contact lenses. Mycelial growth from a corneal sample suggested keratomycosis, but a drastic worsening of the patient’s condition was observed on antifungal drugs. On day 38, panfungal PCR identified Pythium insidiosum, which is an aquatic organism belonging to the oomycete family. Based on the recent literature, this patient was promptly prescribed a systemic and local antibiotic regimen and cure was ultimately achieved. In order to facilitate P. insidiosum identification in future cases, we have generated the first matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) reference spectrum for P. insidiosum. It is planned to deposit this MALDI-TOF MS reference spectrum on an open-access platform and this should allow immediate identification of the pathogen. Finally, this case report also demonstrates that P. insidiosum is emerging outside tropical and subtropical areas. Clinicians and microbiologists should have better knowledge to accurately manage and diagnose this sight-threatening infection. Keywords: Pythiosis, Pythium insidiosum, Keratitis, Panfungal PCR, MALDI-TOF mass spectrometry
Published: 2019
Full Text: View/download PDF

48. Mortality from malaria in France, 2005 to 2014

Author: Kendjo, Eric, Thellier, Marc, Noël, Harold, Jauréguiberry, Stéphane, Septfons, Alexandra, Mouri, Oussama, Gay, Frédérick, Tantaoui, Ilhame, Caumes, Eric, Houzé, Sandrine, Piarroux, Renaud, Musset, Lise, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de Référence du Paludisme [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Santé publique France Guyane, Santé publique France - French National Public Health Agency [Saint-Maurice, France], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique (MERIT - UMR_D 216), Institut de Recherche pour le Développement (IRD)-Université de Paris (UP), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de Parasitologie [Cayenne, Guyane française], Institut Pasteur de la Guyane, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Centre National de Référence du Paludisme [Cayenne, Guyane française] (CNR), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique (MERIT - UMR_D 261), Institut de Recherche pour le Développement (IRD)-Université Paris Cité (UPCité), Réseau International des Instituts Pasteur (RIIP), Centre National de Référence du Paludisme [Cayenne, Guyane française] (CNR - laboratoire associé), Centre Collaborateur OMS pour la surveillance de la résistance aux antipaludiques [Cayenne, Guyane française] (CCOMS), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), The French imported malaria Study group: C. Strady (CHU Reims), Caroline Lohmann (CH du Moenchsberg, Mulhouse), Celine Arriuberge (CH Trousseau, Paris), Emmanuel Grimprel (CH Trousseau, Paris), Jean-Marie Delarbre (CH du Moenchsberg, Mulhouse), Michel Thibault (CH René Dubos, Pontoise), Mohamadou Niang (CHR Orléans), A. Barrans (CH Sète), A. Martin (CH Périgueux), A. Spiegel (DESP Nord), A. Valentin (CHU Toulouse), A.S. Le Guern (Institut Pasteur, Paris), Adela Angoulvant (CHU Kremlin-Bicêtre, Paris), Adeline Dubois (CH Alès), Adrien Genin (CH Pays d'Aix), Agathe Lebuisson (CHU Cochin), Agnes Riche (CH Angoulême), Agnès Durand (Institut Pasteur, Paris), Agnès Fromont (CH Auxerre), Ahmed Aboubacar (CHU de Strasbourg), Ahmed Fateh Ousser (CH Louis Mourier), Aida Taieb (INTS, Paris), Alain Domergue (CH Alès - Cévennes), Alain Gravet (CH du Moenchsberg, Mulhouse), Alain Lecoustumier (CH de Cahors), Albert Faye (CHU Robert Debré, Paris), Alexander Pfaff (CHU de Strasbourg), Alexandra Faussart (CHU Bichat-Claude Bernard, Paris), Alexandre Chlilek (CHU Nîmes), Alice Borel (CHU Amiens), Alice Pérignon (CHU Pitié-Salpêtrière, Paris), Ana Mendes-Mreira (CH La Rochelle), André Gardrat (CH d’Evreux), Ange Kissila (CH Provins), Angèle LI (CH Creil (Laënnec)), Anne Cady (CH Bretagne Atlantique), Anne Debourgogne (CHU de Nancy), Anne Delaval (CHI Robert Ballanger, Aulnay-sous-Bois), Anne Goepp (CHI Villeneuve St Georges), Anne Marfaing-Koka (Hôpital Antoine-Béclère), Anne Pauline Bellanger (CHU Besançon, Jean Minjoz), Anne Vincenot-Blouin (CH Meaux), Anne-Marie Teychene-Coutet (CH Bondy-Jean Verdier), Anne-Sophie Deleplancque (CH Lille), Annick Verhaeghe (CH de Dunkerque), Annie Motard-Picheloup (CHI Fréjus St Raphaël), Antoine Berry (CHU Toulouse), Antoine Huguenin (CHU Reims), Arnaud Bouvet (CH Bretagne Atlantique), Audrey Merens (HIA Begin), Aurelie Roide (CHU Lariboisière, Paris), Aurore Sanson (CH Jacques Cœur, Bourges), Aurélie Fricot (CHU Necker), Aurélie Guigon (CHR Orléans), Benfatallah Dhouha (CHU Necker, Paris), Benjamin Wyplosz (CHU Kremlin-Bicêtre, Paris), Benoît Henri (INTS, Paris), Bernadette Buret (CH Niort), Bernadette Cuisenier (CHU Dijon), Bernadette Worms (CHU Dijon), Bernard Faugère (CH Timone, Marseille), Biligui Sylvestre (CHU Pitié-Salpêtrière, Paris), Boualem Sendid (CH Lille), Bruno Megarbane (CHU Lariboisière, Paris), Bruno Pradines (Département Microbiologie et Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, 13005 Marseille, France, Aix Marseille University, IRD, SSA, AP-HM, VITROME, 13005 Marseille, France, IHU Méditerranée Infection, 13005 Marseille, France, Centre National de Référence du Paludisme, Institut de Recherche Biomédicale des Armées, 13005 Marseille, France), Béatrice Quinet (CH Trousseau, Paris), C. Braidy (CH du Sud Seine et Marne), C. Farrugia (CH de Dourdan), C. Finot (CH de Dreux), Camille Roussel (INTS, Paris), Camille Runel-Belliard (CHU de Bordeaux), Caren Brump (CHU Lariboisière, Paris), Carine Dokoula (CH Jacques Cœur, Bourges), Carmina Camal (CH Louis Mourier), Carole Mackosso (CHU Bichat-Claude Bernard, Paris), Carole Poupon (CH de Gonesse), Caroline Garandeau (CH Angoulême), Catherine Benoit (CH du Sud Seine et Marne), Catherine Branger (CH Louis Mourier), Catherine Brehant (CH La Rochelle), Catherine Desideri-Vaillant (HIA Clermont Tonnerre, Brest), Catherine Kauffmann Lacroix (CH Poitiers), Catherine Lafaurie (CH d’Epernay), Cecile Hombrouck-Alet (CH Blois), Cecile Ramade (Lyon-Croix-Rousse), Celine Damiani (CHU Amiens), Celine Gourmel (CHU Lariboisière, Paris), Chantal Duhamel (CHU Côte de Nacre), Chantal Garabedian (CH Pays d'Aix), Chralotte Chambrion (INTS, Paris), Christelle Morelle (CHU Montpellier), Christelle Pomares Estran (CH Universitaire de Nice), Christelle Prince (CH de Cayenne Andrée Rosemon), Christian Durand (CH Provins), Christian Fulleda (CHU Lariboisière, Paris), Christian Raccurt (CHU Amiens), Christine Chaigneau (GHPSO, Creil), Christine Chemla (CHRU de Reims), Christine Van batten (CH Laënnec, Creil), Christophe Martinaud (HIA Percy, Clamart), Christophe Rapp (HIA Begin), Claire Augé (CHU Bichat-Claude Bernard, Paris), Claire Malbrunot (CH Corbeil Essonne), Claudine Febvre (CH de Montbéliard), Claudine Sarfati (Hôpital Saint-Louis, Paris), Coralie l'Ollivier (CH de la Timone, Marseille), Corinne Huet (Hôpital Louis-Pasteur, Cherbourg-Octeville), Cournac Jean-Marie (HIA Percy, Clamart), Cynthia Pianetti (CH Gabriel Martin, La Réunion), Cécile Angebault (CHU Necker, Paris), Cécile Ficko (HIA Begin), Cécile Garnaud (CHU de Grenoble), Cécile Leprince (CHI Robert Ballanger, Aulnay-sous-Bois), Céliat Merat (CHU Nantes), Céline Dard (CHU de Grenoble), Céline Nourrisson (CHRU Clermont-Ferrand), Céline Tournus (Hôpital Delafontaine, Saint-Denis), Daniel Azjenberg (CHU Dupuytren, Limoges), Daniel Camus (CH Lille), Daniel Lusina (CHI Robert Ballanger, Aulnay-sous-Bois), Daniel Parzy (IMTSSA, Marseille), Denis Pons (CHRU Clermont-Ferrand), Denis Filisetti (CHU Strasbourg), Denis Malvy (CHU de Bordeaux), Didier Basset (CHU Montpellier), Didier Jan (CH Laval), Didier Poisson (CHR Orléans), Didier Raffenot (CH Chambéry), Dieudonné Bemba (CH Bondy-Jean Verdier), Dominique Maubon (CHU de Grenoble), Dominique Mazier (CHU Pitié-Salpêtrière, Paris), Dominique Popjora (CH Trousseau, Paris), Dominique Toubas (CHRU de Reims), Dorothée Quino (CHRU Morvan, Brest), Alioune Ndour (INTS, Paris), Ducout Louis (CH de la Côte Basque), Duong Thanh Hai (CHRU Bretonneau), E. Boyer (CH Le Mans), Edgar Ombandza (CH Provins), Edith Mazars (CH de Valenciennes), Elisabeth Buffet (CH de Epernay), Elodie Collin (CHI Robert Ballanger, Aulnay-sous-Bois), Elodie Meynet (CH Annecy Genevois), Emeline Scherer (CHU Besançon, Jean Minjoz), Emilie Fréalle (CH Lille), Emilie Klein (CHU Lariboisière, Paris), Emilie Sitterle (CHU Necker, Paris), Emily Ronez (CHU Lariboisière, Paris), Emmanuel Dutoit (CH Lille), Enrique Casalino (CHU Bichat-Claude Bernard, Paris), Eric Caumes (CHU Pitié-Salpêtrière, Paris), Eric Dannaoui (Hôpital Européen Georges Pompidou, Paris), Eric Gardien (CH de Draguignan, Bordeaux), Eric Kendjo (CHU Pitié-Salpêtrière, Paris),Eric d'Ortenzio (CHU Bichat-Claude Bernard, Paris), Ermanno Candolfi (CHU de Strasbourg), Estelle Perraud-Cateau (CH Poitiers), Eterne Twizeyimana (CH du Cotentin), F. Roblot (CH Poitiers), Fabienne Pateyron (CH Provins), Fabrice Bruneel (CH de Versailles, André Mignot), Fabrice Legros (CNR du paludisme), Fabrice Simon (HIA Laveran), Fakhri Jeddi (CHU Nantes), Farida M. Benaoudia (CH Troyes), Faïzi Ajana (CH Tourcoing), Felix Djossou (CH de Cayenne Andrée Rosemon), Firouze Banisadr (CHRU de Reims), Florent Morio (CHU Nantes), Francis Derouin (Hôpital Saint-Louis, Paris), Francois Moussel (CH François-Quesnay, Mantes-La-Jolie), Francoise Foulet (CHU Henri Mondor), François Peyron (Lyon-Croix-Rousse), Françoise Benoit-Vical (CHU Toulouse), Françoise Botterel (CHU Henri Mondor), Françoise Gayandrieu (CHU Nantes), Françoise Schmitt (CH du Moenchsberg, Mulhouse), Frederic Ariey (CHU Cochin, Paris), Frédéric Grenouillet (CHU Jean Minjoz, Besançon), Frédéric Sorge (CHU Necker), Frédérique Gay (CHU Pitié-Salpêtrière, Paris), Frédérique Foudrinier (CHRU de Reims), G. Courrouble (CH Blois), G. Gallou (CH de Falaise), G. Julienne (CH Belfort), G. Philippon (Centre Médical CMETE, Paris), Gauthier Pean-de-Ponfilly (CHU Lariboisière, Paris), Geneviève Grise (CH d’Elbeuf), Ghania Belkacem Belkadi (CH Tenon), Gilbert Lorre (CHD La Roche-sur-Yon), Gilles Gargala (CHU Rouen), Gilles Nevez (CHRU Morvan, Brest), Gisele Dewulf (CH de Valenciennes), Guillaume Désoubeaux (CHRU Bretonneau, Tours), Guillaume Escriou (CHU Bichat-Claude Bernard, Paris), Guillaume Le Loup (CH Tenon, Paris), Guillaume Menard (HIA Saint-Anne, Toulon), Guy Carroger (CH Jacques Cœur, Bourges), Guy Galeazzi (CH Louis Mourier), Gwénaël le Moal (CH Poitiers), Hana Talabani (CHU Cochin, Paris), Hanene Abid (CHU Necker, Paris), Helene Broutier (CHI Robert Ballanger, Aulnay-sous-Bois), Herve Pelloux (CHU de Grenoble), Houria Ichou (CH Louis Mourier), Hugo Laurent (CHU Lariboisière, Paris), Hélène Broutier (CH Meaux), Hélène Lapillonne (CH Trousseau, Paris), Hélène Yera (CHU Cochin, Paris), Hélène savini (HIA Laveran), I. Hermes (CH Saint-Malo), Ilhame Tantaoui (CHU Pitié-Salpêtrière, Paris), Isabelle Poilane (CH Bondy-Jean Verdier), Isabelle Amouroux (Hôpital Antoine-Béclère), Isabelle Mazurier (Hôpitaux Civils de Colmar), Isabelle Salimbeni (CH de Cannes), Isabelle Tawa (Centre Médical CMETE, Paris), J Cuziat (CH Saint-Nazaire), J. Bernard Poux (CH de Val d'Ariège - Foix), J. Heurtet (CH Beauvais), J. Rome (CH de Fougères), J. Truchot (CHU Lariboisière, Paris), J.M. Segalin (CHR Orleans), Jacques Gaillat (CH Annecy Genevois), Jacques Le bras (CHU Bichat-Claude Bernard, Paris), Jacques Thevenot (Centre Médical CMETE, Paris), Jacques Vaucel (CH Saint-Brieuc), Jean Dunand (Hôpital Ambroise Paré), Jean Benjamin Murat (CH de Roanne), Jean Marie Trapateau (CH Angoulême), Jean Yves Peltier (CHI Poissy-st-germain), Jean-Etienne Pilo (HIA Begin), Jean-Francois Magnaval (CHU Toulouse), Jean-François Faucher (CHU Jean Minjoz, Limoge), Jean-Paul Boutin (DESP Sud), Jean-Paul Couaillac (CH de Cahors), Jean-Philippe Breux (CH Cholet), Jean-Pierre Hurst (CH Jacques Monod, Le Havre), Jean-Yves Siriez (CHU Robert Debré, Paris), Jean-philippe Bouchara (CHU Angers), Jerome Clain (CHU Bichat-Claude Bernard, Paris), Jerome Naudin (CHU Robert Debré, Paris), Jordan Leroy (CH Lille), Josette Jehan (CH du Cotentin), Joudia Najid (CHU Pitié-Salpêtrière, Paris), Judith Gorlicki (CHU Lariboisière, Paris), Julie Bonhomme (CHU Côte de Nacre), Julie Brunet (CHU de Strasbourg), Jérome Guinard (CHR Orleans), Karima Cheikh (CHU Henri Mondor), L. Pougnet (HIA Clermont Tonnerre, Brest), Lauren Pull (CHU Robert Debré, Paris), Laurence Millon (CHU Jean Minjoz, Besançon), Laurence Campergue-Mayer (CH Avignon), Laurence Estepa (CH Blois), Laurence Lachaud (CHU Nîmes), Laurent Aaron (CH Jacques Cœur, Bourges), Laurent Bret (CHR Orléans), Laurent Guillaume (CH Blois), Liliane Ciceron (CHU Pitié-Salpêtrière, Paris), Lionnel Bertaux (CNR du paludisme), Lise Musset (Institut Pasteur, Guyane), Louise Basmacyan (CHU Dijon), Loïc Favennec (CHU Rouen), Luce Landraud (CH Louis Mourier), Lucile Cadot (CH Alès - Cévennes), Ludovic de Gentile (CHU Angers), Luis Macias (CHU Bichat-Claude Bernard, Paris), Luu-ly Pham (CHU Kremlin-Bicêtre, Paris), M. Cambon (CHRU Clermont-Ferrand), M.F. Biava (CHU de Nancy), M.H. Kiefer (CH du Moenchsberg), M.P. Carlotti (CNR du paludisme), Madeleine Fontrouge (CH de Gonesse), Marc Pihet (CHU Angers), Marc Thellier (CHU Pitié-Salpêtrière, Paris), Marie-Catherine Receveur (CHU de Bordeaux), Marie-Claire Machouart (CHU de Nancy), Marie-Elisabeth Bougnoux (CHU Necker, Paris), Marie-Laure Bigel (CH François-Quesnay, Mantes-la-Jolie), Marie-Laure Darde (CHU Dupuyrien, Limoges), Marie-Nadège Bachelier (CH Jacques Cœur, Bourges), Marion Almeras (CH Béziers), Marion Leterrier (CHU Nantes), Marion Leterrier (CHD La Roche-sur-Yon), Martin Danis (CHU Pitié-Salpêtrière, Paris), Martin G (CH du Cotentin), Martine Bloch (CH Louis Mourier), Martine Liance (CHU Henri Mondor, Paris), Marylin Madamet (IMTSSA, Marseille), Matthieu Revest (CHU Pontchaillou, Rennes),Matthieu Mechain (CHU de Bordeaux), Maxime Thouvenin (CH Troyes), Mermond Sylvain (Institut Pasteur, Nouméa), Michel Develoux (CH Tenon, Paris), Michel Miegeville (CHU Nantes), Milène Sasso (CHU Nîmes), Mohamed Diaby (CH Vernon), Monique Marty (CH La Rochelle), Monique Greze (CH Albi), Monique Lemoine (CHU Bichat-Claude Bernard, Paris), Mouri Oussama (CHU Pitié-Salpêtrière, Paris), Muriel Cornet (Hôpital Hôtel-Dieu, Paris), Muriel Mimoun Ayache (CH Trousseau), Muriel Nicolas (CHU Pointe-à-Pitre / Abymes), Muriel Roumier (CH Arles), Muriel Silva (CH Jacques Monod), Mylène Penot (CERBA), Myriam Gharbi (CHU Bichat-Claude Bernard, Paris), Nadia Guennouni (CHU Bichat-Claude Bernard, Paris), Nadine Godineau (Hôpital Delafontaine, Saint-Denis), Naima Dahane (CHU Cochin, Paris), Nathalie Bourgeois (CHU Montpellier), Nathalie Desuremain (CH Trousseau, Paris), Nathalie Fauchet (CHI de Créteil), Nathalie Parez (CH Louis Mourier), Nathalie Wilhelm (CH de Cahors), Nawel Ait-Ammar (Hôpital Ambroise Paré), Nayla Nassar (CH Auxerre), Nicolas Argy (CHU Bichat-Claude Bernard, Paris), Nicolas Blondiaux (CH Tourcoing), Nicolas Taudon (CERBA), Nicole Desbois-Nogard (CHU de la Martinique), Noura Hassouni (CHU Necker), Odile Bouret-Dubouis (CH Bretagne Atlantique), Odile Eloy (CH de Versailles, André Mignot), Odile Falguiere (CH Béziers), Odile Fenneteau (CHU Robert Debré, Paris), Olivia Bandin (Hôpital Saint-Camille/Bry-sur-Marne), Olivier Albert (CHU de Bordeaux), Olivier Bouchaud (CH Bobigny-Avicenne), Olivier Patey (CHI Villeneuve St. Georges), Olivier Rogeaux (CH Chambéry), P. Clergeau (CH Sallanches), P. Daumain (CH de Dourdan), P.H. Consigny (Institut Pasteur, Paris), Paméla Chauvin (CHU Toulouse), Pascal Delaunay (CH Universitaire de Nice), Pascal Hazera (CH Saint-Lo), Pascal Houze (Hôpital Saint Louis, Paris), Pascal Millet (CHU de Bordeaux), Pascal Pouedras (CH Bretagne Atlantique), Pascale Penn (CH Le Mans), Patrice Agnamey (CHU Amiens), Patrice Bourrée (CHU Kremlin-Bicêtre, Paris), Patricia Barbut (CH Longjumeau), Patricia Brugel (CH Antibes Juan-Les-Pins), Patricia Roux (CH Saint-Antoine, Paris), Patrick Leguen (HIA Clermont Tonnerre, Brest), Patrick Valayer (CH Notre-Dame de la Miséricorde), Pauline Caraux-Paz (CHI Villeneuve St Georges), Pauline Touroultjupin (CH Cholet), Philippe Abboud (CHU Rouen), Philippe Cormier (CH d’Evry), Philippe Minodier (CH Marseille Nord), Philippe Moskovtchenko (Hôpitaux Civils de Colmar), Philippe Parola (CH Marseille Nord), Philippe Poirier (CHRU Clermont-Ferrand), Philippe Stolidi (CH Aubagne), Pierre Patoz (CH Tourcoing), Pierre Buffet (INTS, Paris), Pierre Buffet (CHU Pitié-Salpêtrière, Paris), Pierre Flori (CH Saint-Etienne), Pierre Marty (CH Universitaire de Nice), Pierre Mornand (CH Trousseau, Paris), Pinel Claudine (CHU de Grenoble), R. Dahan (CHU de Strasbourg), R. Devallière (CH Saint-Nazaire), R. Mazataud (CH Vitry le François), Rahaf Haj Hamid (CH Louis Mourier), Regis Courtin (CHU Pitié-Salpêtrière, Paris), Renaud Blonde (CHU Robert Debré, Paris), René Nabias (CHI Poissy-st-germain), Roland Fabre (HIA Begin), Rose-Anne Lavergne (CHU Nantes), Roxane Courtois (CH Cholet), Rym Chouk Turki (CHU Henri Mondor), Rémy Durand (CH Bobigny-Avicenne), Réné Nabias (CHU Necker, Paris), Sabah Kubab (CH Corbeil Essonne), Sabine Lasserre (CH Trousseau, Paris), Samia Hamane (Hôpital Saint-Louis, Paris), Sandrine Cojean (CHU Bichat-Claude Bernard, Paris), Sandrine Houze (CHU Bichat-Claude Bernard, Paris), Sophie Matheron (CHU Bichat-Claude Bernard, Paris), Sorya Belaz (CHU Pontchaillou, Rennes), Stephane Jaureguiberry (CHU Pitié-Salpêtrière, Paris), Stephane Ranque (CH de la Timone, Marseille), Stephanie Dulucq (CHU de Bordeaux), Stéphane Bretagne (Hôpital Saint-Louis, Paris), Stéphane Pelleau (Institut Pasteur, Guyane), Stéphane Picot (Hospices Civils de Lyon), Sylvain Clauser (Hôpital Ambroise Paré), Sylviane Chevrier (CHU Pontchaillou, Rennes), Sylviane Dydymski (CHRU Clermont-Ferrand), Sylvie Lariven (CHU Bichat-Claude Bernard, Paris), Sylvie Lhopital (CH Vernon), Sylvie Maurellet Evrard (CHI Villeneuve St Georges), Sylvie Roulaud (CH Angouleme), Sébastien Larréché (HIA Begin), Thi-Hai-Chau Trinh (CHR Orléans), Thierry Ancelle (CHU Cochin, Paris), Thierry Pistone (CHU de Bordeaux), Thomas Hanslik (Hôpital Ambroise Paré), Thomas Guimard (CHD La Roche-sur-Yon), Timothée Klopfenstein (CHU Besançon, Jean Minjoz), Valerie Fuster-Dumas (CHU de Bordeaux), Veronique Blanc-Amrane (CH Antibes Juan-Les-Pins), Veronique Delcey (CHU Lariboisière, Paris), Veronique Sarrasin-Hubert (CHU Bichat-Claude Bernard, Paris), Vincent Foissaud (HIA Percy, Clamart), Virginie Mouton-Rioux (CH Bretagne Atlantique), Virginie Vitrat (CH Annecy Genevois), Véronique Jan-Lasserre (CH Lagny-sur-Marne), Xavier Nicolas (HIA Clermont Tonnerre, Brest), Y. Costa (CH Lagny-sur-Marne), Yassamine Lazrek (Institut Pasteur, Guyane), Yaye Senghor (Hôpital Saint Joseph, Paris), Yohann Le Govic (CHU Angers), Yves Guimard (CH Jacques Cœur, Bourges), Yves Poinsignon (CH Bretagne Atlantique), Claude flamand (Institut Pasteur, Guyane), C.N. guyen (CH Trousseau, Paris), G. Noël (CH Marseille Nord), G. Soula (CH Marseille Nord), J.M.Didier (CH Vesoul), M.F. Raynaud (CH Antibes Juan-Les-Pins), M. Julien (CH Béziers), M. Morillon (HIA Laveran), M.P. Carlotti (IMTSSA), P. Chantelat (CH Vesoul), P. Dussert (CH Belfort), P. Ralaimazava (CH Bobigny-Avicenne), S. Zaouche (CHU Necker, Paris), Élodie Lesteven (CHU Lariboisière, Paris)., Musset, Lise, Centre National de Référence du Paludisme [CHU Pitié-Salpétrière] (CNRpalu), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Subjects: Plasmodium, Epidemiology, FNRCm, MESH: Hospitalization, Mark and recapture, 0302 clinical medicine, MESH: Aged, 80 and over, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, MESH: Child, 030212 general & internal medicine, MESH: Incidence, MESH: Travel, Imported malaria, media_common, MESH: Aged, MESH: Middle Aged, MESH: Infant, 3. Good health, MESH: Young Adult, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, surveillance, France, Sex ratio, MESH: Medical Record Linkage, MESH: Disease Notification, 030231 tropical medicine, Notifiable disease, MESH: Malaria, capture-recapture, malaria, MESH: Population Surveillance, 03 medical and health sciences, MESH: Cross-Sectional Studies, Virology, parasitic diseases, medicine, media_common.cataloged_instance, European union, MESH: Communicable Diseases, Imported, MESH: Adolescent, MESH: Hospitals, University, MESH: Humans, business.industry, MESH: Child, Preschool, Public Health, Environmental and Occupational Health, MESH: Adult, medicine.disease, Confidence interval, MESH: Male, Metropolitan France, MESH: France, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, travellers, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, MESH: Female, Malaria, Demography
Abstract: Introduction Malaria is a notifiable disease in all European Union and European Economic Area countries except Belgium and France, where only autochthonous malaria is notifiable. Although morbidity caused by malaria has been assessed, little is known about mortality incidence. Objective Our aim was to estimate the number of imported malaria-related deaths in hospital in metropolitan France. Methods We matched individual deaths reported between 1 January 2005 and 31 December 2014 to the French National Reference Centre for malaria (FNRCm) with malaria-related deaths from two other sources: the French National Registry on medical causes of death and the French national hospital discharge database. A capture–recapture method with log-linear modelling was used. Age, sex and place of death stratification were applied to remove heterogeneity. Results The estimated malaria-related deaths in metropolitan France during the study period were 205 (95% confidence interval (CI): 191–219). The annual mean number of malaria-related deaths was estimated at 21 (95% CI: 19–22). The FNRCm malaria-related deaths surveillance had a 38% sensitivity (95% CI: 32–44). Among 161 in-hospital individual malaria-related deaths reported from three data sources, the sex ratio (male to female) was 2.6. Median age of the patients was 57 years, ranging from 1 to 89 years. Conclusion The pertinent finding of this report is that malaria-related death records were significantly less* complete than case records. Therefore, data comparison of imported malaria morbidity and mortality between countries should imperatively be assessed using standard indicators weighted according to the completeness of health surveillance systems.
Published: 2020

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

48 results on '"Céline Dard"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources